| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.661 | 0.004 | 0.661 | Cyclin-dependent kinase 1 inhibitor | |||
| 0.506 | 0.012 | 0.506 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.208 0.087 DBMET02707 0.337 0.038 DBMET02709 0.4 0.025 DBMET02710 | ||
| 0.495 | 0.002 | 0.495 | Chymotrypsin inhibitor | 0.273 0.005 DBMET02707 0.077 0.058 DBMET02709 | ||
| 0.514 | 0.022 | 0.696 | GABA C receptor rho-3 antagonist | 0.42 0.053 DBMET02707 0.498 0.026 DBMET02708 0.679 0.004 DBMET02709 0.696 0.003 DBMET02710 | DBMET02710 | |
| 0.503 | 0.014 | 0.503 | Dyrk kinase inhibitor | 0.193 0.102 DBMET02707 0.348 0.038 DBMET02709 0.389 0.028 DBMET02710 | ||
| 0.44 | 0.006 | 0.44 | Cyclin-dependent kinase 2 inhibitor | 0.106 0.064 DBMET02709 | ||
| 0.434 | 0.039 | 0.742 | Streptokinase A inhibitor | 0.742 0.007 DBMET02707 0.49 0.03 DBMET02708 0.256 0.099 DBMET02710 0.168 0.156 DBMET02711 | DBMET02707 | |
| 0.448 | 0.055 | 0.495 | 15-Lipoxygenase inhibitor | 0.363 0.092 DBMET02707 0.373 0.086 DBMET02709 0.495 0.041 DBMET02710 | DBMET02710 | |
| 0.389 | 0.012 | 0.389 | Cyclin-dependent kinase inhibitor | |||
| 0.376 | 0.01 | 0.376 | Glycogen synthase kinase-3 inhibitor | |||
| 0.39 | 0.033 | 0.423 | Hypoxia-inducible factor 1 alpha inhibitor | 0.423 0.025 DBMET02707 0.196 0.156 DBMET02708 0.24 0.11 DBMET02709 0.315 0.059 DBMET02710 | DBMET02707 | |
| 0.333 | 0.018 | 0.333 | TRKC antagonist | 0.31 0.024 DBMET02709 0.182 0.078 DBMET02710 | ||
| 0.406 | 0.095 | 0.543 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.373 0.126 DBMET02708 0.543 0.018 DBMET02709 0.439 0.069 DBMET02710 | DBMET02709 | |
| 0.321 | 0.012 | 0.321 | Glycogen synthase kinase-3 beta inhibitor | |||
| 0.342 | 0.036 | 0.422 | Amyloid beta aggregation inhibitor | 0.172 0.094 DBMET02709 0.422 0.022 DBMET02710 0.203 0.076 DBMET02711 | DBMET02710 | |
| 0.302 | 0.001 | 0.302 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.123 0.005 DBMET02707 0.115 0.007 DBMET02708 0.143 0.004 DBMET02709 0.111 0.008 DBMET02710 | ||
| 0.386 | 0.115 | 0.407 | Transcription factor inhibitor | 0.407 0.107 DBMET02707 0.239 0.194 DBMET02709 0.222 0.208 DBMET02710 0.235 0.198 DBMET02711 | DBMET02707 | |
| 0.288 | 0.02 | 0.299 | Amyloid beta precursor protein antagonist | 0.158 0.093 DBMET02707 0.294 0.019 DBMET02709 0.299 0.017 DBMET02710 | DBMET02710 | |
| 0.324 | 0.059 | 0.324 | Sodium/bile acid cotransporter inhibitor | 0.292 0.086 DBMET02707 0.305 0.074 DBMET02710 0.198 0.191 DBMET02711 | ||
| 0.273 | 0.01 | 0.388 | Ferrochelatase inhibitor | 0.101 0.07 DBMET02707 0.237 0.015 DBMET02708 0.388 0.004 DBMET02709 0.287 0.009 DBMET02710 | DBMET02709 | |
| 0.383 | 0.122 | 0.386 | Apoptosis agonist | 0.386 0.12 DBMET02710 | DBMET02710 | |
| 0.298 | 0.038 | 0.761 | Peroxidase inhibitor | 0.295 0.038 DBMET02707 0.299 0.038 DBMET02708 0.655 0.004 DBMET02709 0.761 0.002 DBMET02710 0.6 0.004 DBMET02711 | DBMET02710 | |
| 0.268 | 0.016 | 0.268 | Ribosomal protein S6 kinase inhibitor | 0.229 0.027 DBMET02709 0.138 0.074 DBMET02710 | ||
| 0.282 | 0.036 | 0.404 | RNA-directed DNA polymerase inhibitor | 0.273 0.039 DBMET02707 0.362 0.022 DBMET02708 0.378 0.02 DBMET02709 0.404 0.018 DBMET02710 | DBMET02710 | |
| 0.276 | 0.047 | 0.492 | Tyrosine 3 hydroxylase inhibitor | 0.251 0.067 DBMET02707 0.264 0.056 DBMET02708 0.392 0.009 DBMET02709 0.492 0.004 DBMET02710 0.193 0.148 DBMET02711 | DBMET02710 | |
| 0.246 | 0.018 | 0.291 | Hexokinase inhibitor | 0.137 0.095 DBMET02707 0.252 0.017 DBMET02709 0.291 0.012 DBMET02710 | DBMET02710 | |
| 0.276 | 0.053 | 0.373 | DNA synthesis inhibitor | 0.223 0.09 DBMET02707 0.242 0.072 DBMET02708 0.345 0.031 DBMET02709 0.373 0.026 DBMET02710 0.18 0.153 DBMET02711 | DBMET02710 | |
| 0.255 | 0.035 | 0.286 | I kappa B kinase epsilon inhibitor | 0.158 0.111 DBMET02707 0.139 0.133 DBMET02708 0.286 0.02 DBMET02709 0.282 0.022 DBMET02710 | DBMET02709 | |
| 0.335 | 0.117 | 0.335 | Analgesic | |||
| 0.24 | 0.022 | 0.253 | Anesthetic local | 0.253 0.019 DBMET02709 0.224 0.026 DBMET02710 | DBMET02709 | |
| 0.219 | 0.004 | 0.219 | Guanylate cyclase stimulant | |||
| 0.217 | 0.01 | 0.365 | GABA C receptor antagonist | 0.169 0.022 DBMET02707 0.149 0.03 DBMET02708 0.365 0.004 DBMET02709 0.356 0.004 DBMET02710 | DBMET02709 | |
| 0.26 | 0.056 | 0.389 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.389 0.017 DBMET02709 0.259 0.056 DBMET02710 | DBMET02709 | |
| 0.229 | 0.036 | 0.229 | Protein-tyrosine kinase Lyn inhibitor | 0.165 0.059 DBMET02709 | ||
| 0.196 | 0.005 | 0.196 | Purinergic P2X2 antagonist | 0.161 0.009 DBMET02707 0.118 0.022 DBMET02709 0.127 0.018 DBMET02710 | ||
| 0.241 | 0.05 | 0.35 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.35 0.017 DBMET02709 0.255 0.043 DBMET02710 | DBMET02709 | |
| 0.209 | 0.019 | 0.538 | GABA C receptor agonist | 0.17 0.027 DBMET02707 0.233 0.015 DBMET02708 0.538 0.003 DBMET02709 0.524 0.003 DBMET02710 | DBMET02709 | |
| 0.191 | 0.009 | 0.191 | CDK1/cyclin B1 inhibitor | |||
| 0.229 | 0.05 | 0.34 | Nitric-oxide synthase stimulant | 0.228 0.051 DBMET02707 0.221 0.059 DBMET02708 0.313 0.009 DBMET02709 0.34 0.005 DBMET02710 | DBMET02710 | |
| 0.307 | 0.13 | 0.479 | Antibacterial | 0.363 0.095 DBMET02707 0.335 0.111 DBMET02709 0.404 0.075 DBMET02710 0.479 0.047 DBMET02711 | DBMET02711 | |
| 0.18 | 0.003 | 0.18 | Guanylate cyclase 1 stimulant | |||
| 0.233 | 0.062 | 0.369 | MAP kinase kinase 2 inhibitor | 0.145 0.126 DBMET02707 0.255 0.051 DBMET02708 0.369 0.017 DBMET02709 0.359 0.019 DBMET02710 | DBMET02709 | |
| 0.314 | 0.15 | 0.534 | 5 Hydroxytryptamine release inhibitor | 0.322 0.142 DBMET02707 0.292 0.175 DBMET02708 0.509 0.029 DBMET02709 0.534 0.023 DBMET02710 0.254 0.222 DBMET02711 | DBMET02710 | |
| 0.22 | 0.058 | 0.408 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.192 0.08 DBMET02707 0.158 0.13 DBMET02708 0.359 0.011 DBMET02709 0.408 0.007 DBMET02710 0.187 0.085 DBMET02711 | DBMET02710 | |
| 0.199 | 0.043 | 0.199 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.172 0.057 DBMET02709 0.186 0.049 DBMET02710 | ||
| 0.173 | 0.018 | 0.173 | DNA directed RNA polymerase inhibitor | 0.088 0.072 DBMET02709 | ||
| 0.229 | 0.075 | 0.267 | MAP-kinase-activated kinase 5 inhibitor | 0.267 0.049 DBMET02709 0.243 0.064 DBMET02710 | DBMET02709 | |
| 0.17 | 0.017 | 0.174 | DNA repair enzyme inhibitor | 0.109 0.098 DBMET02707 0.112 0.091 DBMET02708 0.174 0.016 DBMET02709 0.172 0.017 DBMET02710 | DBMET02709 | |
| 0.168 | 0.017 | 0.306 | Nitric-oxide synthase inhibitor | 0.105 0.052 DBMET02707 0.306 0.004 DBMET02708 0.189 0.011 DBMET02709 0.144 0.025 DBMET02710 | DBMET02708 | |
| 0.168 | 0.017 | 0.168 | Folate antagonist | 0.14 0.026 DBMET02707 0.098 0.069 DBMET02708 0.119 0.039 DBMET02709 0.099 0.067 DBMET02710 | ||
| 0.191 | 0.041 | 0.21 | CDC-like kinase 1 inhibitor | 0.21 0.031 DBMET02709 0.185 0.045 DBMET02710 | DBMET02709 | |
| 0.187 | 0.037 | 0.346 | GABA C receptor rho-2 antagonist | 0.141 0.087 DBMET02707 0.187 0.037 DBMET02708 0.346 0.004 DBMET02709 0.331 0.004 DBMET02710 | DBMET02709 | |
| 0.16 | 0.009 | 0.203 | Myeloperoxidase inhibitor | 0.097 0.039 DBMET02707 0.082 0.062 DBMET02708 0.181 0.007 DBMET02709 0.203 0.005 DBMET02710 | DBMET02710 | |
| 0.16 | 0.011 | 0.16 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.103 0.034 DBMET02709 0.09 0.042 DBMET02710 | ||
| 0.221 | 0.072 | 0.39 | MAP kinase kinase 3 inhibitor | 0.25 0.032 DBMET02708 0.39 0.003 DBMET02709 0.282 0.012 DBMET02710 | DBMET02709 | |
| 0.17 | 0.02 | 0.288 | Adenylate kinase inhibitor | 0.123 0.041 DBMET02707 0.149 0.027 DBMET02708 0.288 0.008 DBMET02709 0.261 0.009 DBMET02710 0.115 0.048 DBMET02711 | DBMET02709 | |
| 0.159 | 0.016 | 0.306 | NADH dehydrogenase inhibitor | 0.127 0.025 DBMET02707 0.152 0.017 DBMET02708 0.271 0.007 DBMET02709 0.306 0.006 DBMET02710 | DBMET02710 | |
| 0.162 | 0.021 | 0.299 | HIV-1 integrase (Overall Integration) inhibitor | 0.21 0.01 DBMET02707 0.123 0.038 DBMET02708 0.286 0.004 DBMET02709 0.299 0.004 DBMET02710 0.086 0.069 DBMET02711 | DBMET02710 | |
| 0.143 | 0.008 | 0.185 | Purinergic P2X1 antagonist | 0.12 0.011 DBMET02707 0.067 0.035 DBMET02708 0.169 0.005 DBMET02709 0.185 0.004 DBMET02710 0.06 0.043 DBMET02711 | DBMET02710 | |
| 0.148 | 0.016 | 0.28 | Inducible nitric-oxide synthase inhibitor | 0.096 0.04 DBMET02707 0.28 0.004 DBMET02708 0.156 0.015 DBMET02709 0.118 0.025 DBMET02710 | DBMET02708 | |
| 0.184 | 0.053 | 0.19 | ATPase inhibitor | 0.185 0.052 DBMET02709 0.19 0.046 DBMET02710 | DBMET02710 | |
| 0.187 | 0.058 | 0.269 | Heat shock protein 90 alpha antagonist | 0.138 0.101 DBMET02707 0.196 0.052 DBMET02709 0.269 0.021 DBMET02710 | DBMET02710 | |
| 0.175 | 0.045 | 0.18 | Hemostatic | 0.131 0.095 DBMET02708 0.178 0.043 DBMET02709 0.18 0.042 DBMET02710 | DBMET02710 | |
| 0.158 | 0.031 | 0.158 | Cyclin-dependent kinase 9 inhibitor | 0.138 0.038 DBMET02709 0.115 0.049 DBMET02710 | ||
| 0.182 | 0.056 | 0.2 | Cytidine deaminase inhibitor | 0.124 0.097 DBMET02707 0.2 0.048 DBMET02709 0.143 0.08 DBMET02710 | DBMET02709 | |
| 0.139 | 0.013 | 0.241 | Glutamate release inhibitor | 0.105 0.035 DBMET02708 0.241 0.004 DBMET02709 0.219 0.004 DBMET02710 | DBMET02709 | |
| 0.142 | 0.017 | 0.41 | Toll-Like receptor 3 antagonist | 0.158 0.012 DBMET02708 0.41 0.002 DBMET02709 0.254 0.004 DBMET02710 | DBMET02709 | |
| 0.177 | 0.055 | 0.273 | Catenin beta inhibitor | 0.176 0.057 DBMET02707 0.245 0.012 DBMET02709 0.273 0.008 DBMET02710 | DBMET02710 | |
| 0.202 | 0.08 | 0.345 | Pyruvate kinase inhibitor | 0.328 0.041 DBMET02707 0.234 0.066 DBMET02709 0.345 0.035 DBMET02710 0.331 0.04 DBMET02711 | DBMET02710 | |
| 0.136 | 0.015 | 0.136 | CDK1/cyclin B inhibitor | |||
| 0.299 | 0.181 | 0.299 | MAP kinase 1 inhibitor | 0.289 0.193 DBMET02709 | ||
| 0.128 | 0.01 | 0.128 | Urokinase inhibitor | 0.053 0.031 DBMET02708 0.078 0.022 DBMET02709 0.05 0.033 DBMET02710 | ||
| 0.164 | 0.048 | 0.207 | M17 leucyl aminopeptidase inhibitor | 0.207 0.03 DBMET02707 0.126 0.073 DBMET02709 0.142 0.06 DBMET02710 0.106 0.094 DBMET02711 | DBMET02707 | |
| 0.141 | 0.025 | 0.312 | GABA C receptor rho-1 antagonist | 0.098 0.066 DBMET02707 0.149 0.022 DBMET02708 0.312 0.003 DBMET02709 0.287 0.004 DBMET02710 | DBMET02709 | |
| 0.239 | 0.124 | 0.239 | Immunomodulator | 0.217 0.144 DBMET02709 | ||
| 0.129 | 0.014 | 0.185 | Carbamoyl phosphate synthetase inhibitor | 0.07 0.035 DBMET02707 0.095 0.022 DBMET02708 0.185 0.008 DBMET02709 0.174 0.009 DBMET02710 | DBMET02709 | |
| 0.131 | 0.016 | 0.131 | Cyclin A2 inhibitor | 0.061 0.046 DBMET02709 | ||
| 0.124 | 0.014 | 0.166 | Granulocyte macrophage colony stimulating factor agonist | 0.099 0.037 DBMET02707 0.109 0.025 DBMET02708 0.166 0.004 DBMET02709 0.161 0.004 DBMET02710 | DBMET02709 | |
| 0.125 | 0.015 | 0.125 | mTOR complex 2 inhibitor | 0.084 0.06 DBMET02708 0.121 0.017 DBMET02709 0.113 0.021 DBMET02710 | ||
| 0.213 | 0.104 | 0.571 | Superoxide dismutase inhibitor | 0.179 0.143 DBMET02707 0.232 0.087 DBMET02708 0.482 0.015 DBMET02709 0.571 0.008 DBMET02710 0.297 0.051 DBMET02711 | DBMET02710 | |
| 0.132 | 0.025 | 0.132 | Pim-3 kinase inhibitor | 0.132 0.025 DBMET02709 0.105 0.041 DBMET02710 | ||
| 0.157 | 0.05 | 0.157 | MAP3K9 inhibitor | |||
| 0.129 | 0.024 | 0.129 | Potassium channel (Voltage-sensitive) activator | 0.129 0.024 DBMET02709 0.087 0.074 DBMET02710 | ||
| 0.138 | 0.034 | 0.138 | CDK/cyclin complex inhibitor | 0.078 0.071 DBMET02709 | ||
| 0.251 | 0.146 | 0.419 | Calcium channel activator | 0.324 0.069 DBMET02707 0.366 0.04 DBMET02708 0.419 0.019 DBMET02709 0.403 0.023 DBMET02710 | DBMET02709 | |
| 0.201 | 0.099 | 0.3 | Antiamyloidogenic | 0.213 0.091 DBMET02709 0.3 0.052 DBMET02710 | DBMET02710 | |
| 0.203 | 0.101 | 0.472 | Aryl hydrocarbon receptor agonist | 0.472 0.027 DBMET02709 0.468 0.027 DBMET02710 | DBMET02709 | |
| 0.114 | 0.012 | 0.164 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.059 0.035 DBMET02707 0.078 0.021 DBMET02708 0.164 0.008 DBMET02709 0.135 0.01 DBMET02710 | DBMET02709 | |
| 0.153 | 0.052 | 0.153 | Tyrosine-protein kinase receptor FLT3 inhibitor | |||
| 0.165 | 0.065 | 0.199 | Cyclin-dependent kinase 8 inhibitor | 0.199 0.036 DBMET02709 0.175 0.056 DBMET02710 | DBMET02709 | |
| 0.187 | 0.088 | 0.279 | 5 Hydroxytryptamine 3E antagonist | 0.186 0.091 DBMET02708 0.279 0.008 DBMET02709 0.224 0.033 DBMET02710 | DBMET02709 | |
| 0.116 | 0.018 | 0.116 | Cyclin A inhibitor | 0.057 0.047 DBMET02709 | ||
| 0.148 | 0.051 | 0.179 | Heat shock protein 70 antagonist | 0.135 0.097 DBMET02708 0.165 0.022 DBMET02709 0.179 0.012 DBMET02710 | DBMET02710 | |
| 0.183 | 0.089 | 0.265 | Clk dual-specificity kinase inhibitor | 0.265 0.049 DBMET02709 0.145 0.119 DBMET02710 | DBMET02709 | |
| 0.172 | 0.078 | 0.319 | Succinate dehydrogenase inhibitor | 0.151 0.11 DBMET02707 0.15 0.112 DBMET02708 0.297 0.011 DBMET02709 0.319 0.008 DBMET02710 0.29 0.012 DBMET02711 | DBMET02710 | |
| 0.119 | 0.025 | 0.206 | Phosphofructokinase-1 inhibitor | 0.067 0.05 DBMET02707 0.084 0.039 DBMET02708 0.189 0.012 DBMET02709 0.206 0.01 DBMET02710 0.07 0.048 DBMET02711 | DBMET02710 | |
| 0.158 | 0.066 | 0.263 | Heat shock protein 90 antagonist | 0.176 0.051 DBMET02709 0.263 0.017 DBMET02710 | DBMET02710 | |
| 0.179 | 0.089 | 0.261 | Focal adhesion kinase 2 inhibitor | 0.261 0.032 DBMET02709 0.191 0.077 DBMET02710 | DBMET02709 | |
| 0.137 | 0.051 | 0.137 | MAP kinase 12 inhibitor | 0.137 0.052 DBMET02709 | ||
| 0.102 | 0.017 | 0.11 | Secretase beta inhibitor | 0.103 0.017 DBMET02708 0.11 0.014 DBMET02709 0.088 0.027 DBMET02710 | DBMET02709 | |
| 0.161 | 0.077 | 0.246 | Protein kinase (CK1) gamma 3 inhibitor | 0.246 0.028 DBMET02709 0.163 0.076 DBMET02710 | DBMET02709 | |
| 0.135 | 0.052 | 0.201 | Beta amyloid protein antagonist | 0.201 0.016 DBMET02709 0.187 0.021 DBMET02710 | DBMET02709 | |
| 0.101 | 0.018 | 0.215 | Biliverdin reductase inhibitor | 0.058 0.043 DBMET02707 0.102 0.018 DBMET02708 0.215 0.005 DBMET02709 0.173 0.007 DBMET02710 | DBMET02709 | |
| 0.098 | 0.015 | 0.098 | Phosphodiesterase VIII inhibitor | 0.071 0.051 DBMET02709 | ||
| 0.109 | 0.027 | 0.182 | Glutamate dehydrogenase inhibitor | 0.069 0.058 DBMET02707 0.081 0.044 DBMET02708 0.182 0.012 DBMET02709 0.179 0.012 DBMET02710 0.133 0.019 DBMET02711 | DBMET02709 | |
| 0.121 | 0.041 | 0.121 | CDK2/cyclin A inhibitor | 0.102 0.056 DBMET02709 | ||
| 0.141 | 0.061 | 0.422 | Alpha-N-acetylglucosaminidase inhibitor | 0.144 0.058 DBMET02708 0.422 0.008 DBMET02709 0.379 0.01 DBMET02710 0.135 0.065 DBMET02711 | DBMET02709 | |
| 0.133 | 0.053 | 0.143 | Protein kinase (CK2) alpha inhibitor | 0.135 0.051 DBMET02709 0.143 0.046 DBMET02710 | DBMET02710 | |
| 0.149 | 0.07 | 0.264 | Protein kinase (CK1) gamma 1 inhibitor | 0.264 0.026 DBMET02709 0.128 0.089 DBMET02710 | DBMET02709 | |
| 0.224 | 0.147 | 0.438 | Transcription factor NF kappa B inhibitor | 0.31 0.089 DBMET02709 0.438 0.055 DBMET02710 0.262 0.119 DBMET02711 | DBMET02710 | |
| 0.12 | 0.042 | 0.161 | Pim-1 kinase inhibitor | 0.161 0.024 DBMET02709 0.097 0.061 DBMET02710 | DBMET02709 | |
| 0.082 | 0.005 | 0.194 | Endothelial nitric-oxide synthase inhibitor | 0.034 0.018 DBMET02707 0.194 0.003 DBMET02708 0.073 0.005 DBMET02709 0.033 0.019 DBMET02710 | DBMET02708 | |
| 0.144 | 0.068 | 0.144 | Tyrosine-protein kinase receptor antagonist | 0.128 0.079 DBMET02709 | ||
| 0.095 | 0.02 | 0.176 | Argininosuccinate synthase inhibitor | 0.067 0.032 DBMET02707 0.09 0.022 DBMET02708 0.176 0.009 DBMET02709 0.155 0.011 DBMET02710 | DBMET02709 | |
| 0.085 | 0.011 | 0.109 | Epithelial sodium channel blocker | 0.064 0.024 DBMET02708 0.109 0.005 DBMET02709 0.103 0.006 DBMET02710 | DBMET02709 | |
| 0.123 | 0.049 | 0.123 | MAP kinase kinase kinase inhibitor | 0.12 0.051 DBMET02709 | ||
| 0.106 | 0.034 | 0.106 | Bromodomain-containing protein 2 inhibitor | 0.103 0.037 DBMET02709 | ||
| 0.139 | 0.068 | 0.148 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.148 0.063 DBMET02710 | DBMET02710 | |
| 0.16 | 0.089 | 0.285 | LIM domain kinase 1 inhibitor | 0.131 0.12 DBMET02708 0.285 0.025 DBMET02709 0.254 0.036 DBMET02710 | DBMET02709 | |
| 0.227 | 0.157 | 0.304 | Vasodilator, coronary | 0.297 0.09 DBMET02709 0.304 0.084 DBMET02710 | DBMET02710 | |
| 0.123 | 0.053 | 0.263 | 5 Hydroxytryptamine 3A agonist | 0.139 0.042 DBMET02708 0.263 0.005 DBMET02709 0.245 0.006 DBMET02710 | DBMET02709 | |
| 0.093 | 0.029 | 0.332 | Phenylalanine 4-hydroxylase inhibitor | 0.086 0.033 DBMET02707 0.075 0.041 DBMET02708 0.214 0.006 DBMET02709 0.332 0.004 DBMET02710 0.307 0.004 DBMET02711 | DBMET02710 | |
| 0.084 | 0.021 | 0.17 | Acyl-CoA dehydrogenase inhibitor | 0.07 0.027 DBMET02708 0.17 0.007 DBMET02709 0.136 0.01 DBMET02710 | DBMET02709 | |
| 0.069 | 0.007 | 0.078 | Dihydrofolate reductase inhibitor | 0.046 0.026 DBMET02708 0.078 0.005 DBMET02709 0.063 0.009 DBMET02710 | DBMET02709 | |
| 0.184 | 0.122 | 0.256 | Peptidyltransferase inhibitor | 0.177 0.134 DBMET02709 0.256 0.047 DBMET02710 0.167 0.154 DBMET02711 | DBMET02710 | |
| 0.093 | 0.034 | 0.093 | HIV-1 reverse transcriptase inhibitor | 0.076 0.045 DBMET02709 | ||
| 0.094 | 0.035 | 0.094 | Caspase 7 inhibitor | 0.092 0.038 DBMET02709 0.077 0.068 DBMET02710 | ||
| 0.089 | 0.03 | 0.089 | MAP3K7 inhibitor | 0.072 0.05 DBMET02709 | ||
| 0.106 | 0.049 | 0.197 | Electrolyte absorption antagonist | 0.094 0.067 DBMET02708 0.197 0.009 DBMET02709 0.156 0.017 DBMET02710 | DBMET02709 | |
| 0.203 | 0.146 | 0.42 | 5 Hydroxytryptamine uptake stimulant | 0.194 0.164 DBMET02708 0.42 0.011 DBMET02709 0.41 0.013 DBMET02710 0.237 0.095 DBMET02711 | DBMET02709 | |
| 0.101 | 0.045 | 0.165 | Histamine N-methyltransferase inhibitor | 0.122 0.029 DBMET02708 0.165 0.01 DBMET02709 0.156 0.012 DBMET02710 | DBMET02709 | |
| 0.174 | 0.12 | 0.756 | Aldehyde oxidase inhibitor | 0.301 0.066 DBMET02707 0.201 0.104 DBMET02708 0.623 0.016 DBMET02709 0.756 0.005 DBMET02710 0.502 0.033 DBMET02711 | DBMET02710 | |
| 0.069 | 0.015 | 0.12 | Glutamate (mGluR group III) agonist | 0.12 0.007 DBMET02709 0.082 0.013 DBMET02710 | DBMET02709 | |
| 0.085 | 0.032 | 0.149 | GABA B receptor agonist | 0.116 0.009 DBMET02707 0.127 0.006 DBMET02708 0.117 0.008 DBMET02709 0.149 0.004 DBMET02710 | DBMET02710 | |
| 0.137 | 0.085 | 0.178 | Ca2+-transporting ATPase inhibitor | 0.134 0.1 DBMET02708 0.178 0.008 DBMET02709 0.177 0.008 DBMET02710 | DBMET02709 | |
| 0.129 | 0.079 | 0.132 | Glycogen synthase kinase-3 alpha inhibitor | 0.132 0.077 DBMET02709 0.126 0.081 DBMET02710 | DBMET02709 | |
| 0.104 | 0.054 | 0.104 | mTOR complex 1 inhibitor | |||
| 0.062 | 0.013 | 0.086 | AICAR transformylase inhibitor | 0.048 0.024 DBMET02707 0.044 0.031 DBMET02708 0.085 0.007 DBMET02709 0.086 0.006 DBMET02710 | DBMET02710 | |
| 0.207 | 0.159 | 0.432 | Cholesterol antagonist | 0.344 0.067 DBMET02709 0.432 0.043 DBMET02710 | DBMET02710 | |
| 0.124 | 0.076 | 0.124 | RET inhibitor | 0.115 0.083 DBMET02709 | ||
| 0.059 | 0.012 | 0.183 | Dihydropteroate synthase inhibitor | 0.042 0.024 DBMET02707 0.065 0.01 DBMET02708 0.156 0.003 DBMET02709 0.183 0.003 DBMET02710 | DBMET02710 | |
| 0.103 | 0.057 | 0.299 | UDP-glucose 4-epimerase inhibitor | 0.1 0.061 DBMET02707 0.109 0.052 DBMET02708 0.269 0.012 DBMET02709 0.299 0.01 DBMET02710 0.12 0.043 DBMET02711 | DBMET02710 | |
| 0.058 | 0.012 | 0.076 | Phosphoglycerate kinase inhibitor | 0.032 0.028 DBMET02707 0.07 0.009 DBMET02709 0.076 0.009 DBMET02710 | DBMET02710 | |
| 0.059 | 0.014 | 0.078 | Cytokine production stimulant | 0.078 0.005 DBMET02709 0.059 0.014 DBMET02710 | DBMET02709 | |
| 0.107 | 0.063 | 0.245 | DOPA decarboxylase inhibitor | 0.099 0.077 DBMET02707 0.097 0.082 DBMET02708 0.176 0.011 DBMET02709 0.245 0.004 DBMET02710 0.093 0.092 DBMET02711 | DBMET02710 | |
| 0.141 | 0.1 | 0.223 | CDC-like kinase 2 inhibitor | 0.223 0.055 DBMET02709 | DBMET02709 | |
| 0.066 | 0.025 | 0.096 | Sphingosine kinase 2 inhibitor | 0.087 0.012 DBMET02709 0.096 0.009 DBMET02710 | DBMET02710 | |
| 0.069 | 0.029 | 0.154 | Heat shock protein 90 beta antagonist | 0.102 0.01 DBMET02709 0.154 0.005 DBMET02710 | DBMET02710 | |
| 0.072 | 0.032 | 0.072 | Phosphatidylinositol kinase inhibitor | |||
| 0.093 | 0.053 | 0.093 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | |||
| 0.081 | 0.043 | 0.133 | MAP kinase kinase 7 inhibitor | 0.081 0.043 DBMET02707 0.082 0.041 DBMET02708 0.109 0.007 DBMET02709 0.133 0.003 DBMET02710 | DBMET02710 | |
| 0.049 | 0.011 | 0.07 | Glutamate (mGluR4) agonist | 0.07 0.007 DBMET02709 0.05 0.011 DBMET02710 | DBMET02709 | |
| 0.07 | 0.032 | 0.102 | I kappa B kinase 2 inhibitor | 0.102 0.012 DBMET02709 0.097 0.014 DBMET02710 | DBMET02709 | |
| 0.051 | 0.014 | 0.127 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.078 0.004 DBMET02707 0.089 0.003 DBMET02708 0.099 0.003 DBMET02709 0.127 0.002 DBMET02710 | DBMET02710 | |
| 0.067 | 0.031 | 0.067 | Cyclin H inhibitor | |||
| 0.236 | 0.2 | 0.276 | DNA directed DNA polymerase inhibitor | 0.25 0.191 DBMET02707 0.252 0.19 DBMET02709 0.276 0.176 DBMET02710 | DBMET02710 | |
| 0.177 | 0.144 | 0.612 | 5 Hydroxytryptamine release stimulant | 0.18 0.141 DBMET02708 0.609 0.014 DBMET02709 0.612 0.013 DBMET02710 | DBMET02710 | |
| 0.069 | 0.036 | 0.107 | Interferon inducer | 0.107 0.01 DBMET02709 0.092 0.016 DBMET02710 | DBMET02709 | |
| 0.081 | 0.05 | 0.143 | Interferon agonist | 0.143 0.011 DBMET02709 0.122 0.016 DBMET02710 | DBMET02709 | |
| 0.097 | 0.065 | 0.41 | Carbonic anhydrase III inhibitor | 0.088 0.077 DBMET02707 0.266 0.008 DBMET02709 0.41 0.004 DBMET02710 0.088 0.077 DBMET02711 | DBMET02710 | |
| 0.053 | 0.022 | 0.092 | Fructose-1,6-bisphosphatase inhibitor | 0.092 0.005 DBMET02709 0.085 0.006 DBMET02710 | DBMET02709 | |
| 0.071 | 0.04 | 0.104 | Exportin-1 inhibitor | 0.104 0.007 DBMET02709 0.077 0.03 DBMET02710 | DBMET02709 | |
| 0.096 | 0.064 | 0.343 | Creatine kinase inhibitor | 0.091 0.071 DBMET02707 0.208 0.009 DBMET02709 0.343 0.004 DBMET02710 | DBMET02710 | |
| 0.035 | 0.004 | 0.035 | Cyclin T1 inhibitor | 0.019 0.012 DBMET02708 0.03 0.005 DBMET02709 0.016 0.015 DBMET02710 | ||
| 0.061 | 0.031 | 0.103 | Ornithine carbamoyltransferase inhibitor | 0.056 0.035 DBMET02708 0.103 0.015 DBMET02709 0.085 0.02 DBMET02710 0.084 0.02 DBMET02711 | DBMET02709 | |
| 0.055 | 0.025 | 0.215 | Sodium/calcium exchanger inhibitor | 0.215 0.003 DBMET02709 0.101 0.005 DBMET02710 | DBMET02709 | |
| 0.069 | 0.042 | 0.069 | Cyclin-dependent kinase 4 inhibitor | |||
| 0.041 | 0.014 | 0.088 | Potassium channel small-conductance Ca-activated activator | 0.061 0.008 DBMET02708 0.088 0.005 DBMET02709 0.029 0.025 DBMET02710 | DBMET02709 | |
| 0.083 | 0.056 | 0.132 | I kappa B kinase inhibitor | 0.132 0.021 DBMET02709 0.123 0.025 DBMET02710 | DBMET02709 | |
| 0.089 | 0.062 | 0.115 | Potassium channel activator | 0.115 0.035 DBMET02709 0.1 0.048 DBMET02710 | DBMET02709 | |
| 0.046 | 0.02 | 0.089 | Alpha 1d adrenoreceptor agonist | 0.089 0.004 DBMET02709 0.073 0.006 DBMET02710 | DBMET02709 | |
| 0.109 | 0.083 | 0.155 | Transcription factor STAT6 inhibitor | 0.118 0.063 DBMET02707 0.148 0.025 DBMET02709 0.155 0.019 DBMET02710 | DBMET02710 | |
| 0.057 | 0.031 | 0.057 | Phosphatidylinositol 3-kinase alpha inhibitor | |||
| 0.057 | 0.031 | 0.093 | Immunoglobulin Fc receptor antagonist | 0.053 0.046 DBMET02708 0.093 0.004 DBMET02709 0.082 0.005 DBMET02710 | DBMET02709 | |
| 0.029 | 0.003 | 0.029 | O6-alkylguanine-DNA alkyltransferase inhibitor | 0.017 0.011 DBMET02709 | ||
| 0.076 | 0.051 | 0.348 | Porphobilinogen synthase inhibitor | 0.264 0.007 DBMET02709 0.348 0.004 DBMET02710 0.123 0.027 DBMET02711 | DBMET02710 | |
| 0.035 | 0.01 | 0.046 | Purinergic P2Y15 antagonist | 0.03 0.017 DBMET02708 0.046 0.005 DBMET02709 0.042 0.006 DBMET02710 | DBMET02709 | |
| 0.108 | 0.083 | 0.267 | M18 aspartyl aminopeptidase inhibitor | 0.224 0.027 DBMET02707 0.267 0.018 DBMET02710 0.127 0.065 DBMET02711 | DBMET02710 | |
| 0.207 | 0.182 | 0.284 | Calpain 2 inhibitor | 0.284 0.124 DBMET02709 0.222 0.169 DBMET02710 | DBMET02709 | |
| 0.037 | 0.015 | 0.04 | ATR kinase inhibitor | 0.04 0.013 DBMET02709 | DBMET02709 | |
| 0.152 | 0.13 | 0.205 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.205 0.069 DBMET02709 0.169 0.107 DBMET02710 | DBMET02709 | |
| 0.133 | 0.111 | 0.257 | CF transmembrane conductance regulator agonist | 0.133 0.111 DBMET02707 0.22 0.013 DBMET02709 0.257 0.005 DBMET02710 | DBMET02710 | |
| 0.04 | 0.019 | 0.074 | Fumarate hydratase inhibitor | 0.074 0.008 DBMET02709 0.064 0.009 DBMET02710 | DBMET02709 | |
| 0.092 | 0.071 | 0.129 | Protein kinase (CK2) inhibitor | 0.083 0.079 DBMET02707 0.118 0.05 DBMET02709 0.129 0.043 DBMET02710 | DBMET02710 | |
| 0.091 | 0.071 | 0.109 | Interleukin 1 beta converting enzyme inhibitor | 0.085 0.081 DBMET02707 0.107 0.049 DBMET02709 0.109 0.047 DBMET02710 | DBMET02710 | |
| 0.065 | 0.045 | 0.072 | Aryl hydrocarbon receptor antagonist | 0.072 0.035 DBMET02709 0.065 0.044 DBMET02710 | DBMET02709 | |
| 0.097 | 0.078 | 0.097 | Cyclin-dependent kinase 5 inhibitor | 0.097 0.078 DBMET02709 | ||
| 0.045 | 0.027 | 0.064 | Histamine H1 receptor agonist | 0.048 0.021 DBMET02708 0.064 0.006 DBMET02709 | DBMET02709 | |
| 0.142 | 0.123 | 0.465 | Phospholipase C inhibitor | 0.142 0.123 DBMET02708 0.368 0.013 DBMET02709 0.465 0.007 DBMET02710 0.438 0.008 DBMET02711 | DBMET02710 | |
| 0.085 | 0.067 | 0.237 | Triose-phosphate isomerase inhibitor | 0.079 0.077 DBMET02708 0.237 0.008 DBMET02709 0.221 0.009 DBMET02710 | DBMET02709 | |
| 0.082 | 0.063 | 0.257 | D-Ala-D-Ala ligase inhibitor | 0.091 0.043 DBMET02707 0.084 0.058 DBMET02708 0.183 0.004 DBMET02709 0.257 0.002 DBMET02710 | DBMET02710 | |
| 0.056 | 0.039 | 0.767 | Alcohol oxidase inhibitor | 0.345 0.004 DBMET02709 0.767 0.003 DBMET02710 | DBMET02710 | |
| 0.049 | 0.032 | 0.051 | Antimetabolite | 0.042 0.038 DBMET02708 0.051 0.031 DBMET02709 0.044 0.036 DBMET02710 | DBMET02709 | |
| 0.033 | 0.016 | 0.063 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.032 0.016 DBMET02708 0.063 0.007 DBMET02709 0.046 0.01 DBMET02710 | DBMET02709 | |
| 0.056 | 0.039 | 0.056 | Bruton tyrosine kinase inhibitor | |||
| 0.049 | 0.033 | 0.067 | Histamine H4 receptor antagonist | 0.067 0.014 DBMET02709 | DBMET02709 | |
| 0.021 | 0.005 | 0.022 | CDK2/cyclin A3 inhibitor | 0.022 0.004 DBMET02709 | DBMET02709 | |
| 0.039 | 0.024 | 0.1 | Glutamate (mGluR8) agonist | 0.037 0.028 DBMET02708 0.1 0.003 DBMET02709 0.094 0.003 DBMET02710 | DBMET02709 | |
| 0.066 | 0.052 | 0.066 | Protein kinase B alpha inhibitor | |||
| 0.039 | 0.025 | 0.065 | Diamine oxidase inhibitor | 0.065 0.008 DBMET02709 0.04 0.023 DBMET02710 | DBMET02709 | |
| 0.051 | 0.037 | 0.128 | Aconitate hydratase inhibitor | 0.128 0.005 DBMET02709 0.097 0.009 DBMET02710 | DBMET02709 | |
| 0.153 | 0.139 | 0.437 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.408 0.036 DBMET02709 0.437 0.03 DBMET02710 | DBMET02710 | |
| 0.088 | 0.074 | 0.185 | Aminopeptidase B inhibitor | 0.085 0.077 DBMET02708 0.185 0.025 DBMET02709 0.184 0.025 DBMET02710 0.177 0.028 DBMET02711 | DBMET02709 | |
| 0.059 | 0.046 | 0.102 | Adenosine A2a receptor antagonist | 0.102 0.024 DBMET02709 0.084 0.03 DBMET02710 | DBMET02709 | |
| 0.052 | 0.039 | 0.074 | Ribonucleoside-diphosphate reductase inhibitor | 0.045 0.044 DBMET02707 0.057 0.036 DBMET02708 0.058 0.035 DBMET02709 0.074 0.027 DBMET02710 0.047 0.043 DBMET02711 | DBMET02710 | |
| 0.129 | 0.116 | 0.129 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.053 | 0.04 | 0.077 | Ribonucleotide reductase inhibitor | 0.059 0.037 DBMET02708 0.06 0.036 DBMET02709 0.077 0.028 DBMET02710 | DBMET02710 | |
| 0.025 | 0.013 | 0.049 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.049 0.004 DBMET02709 0.041 0.004 DBMET02710 | DBMET02709 | |
| 0.064 | 0.053 | 0.119 | Glutamate (mGluR6) antagonist | 0.119 0.005 DBMET02709 0.103 0.009 DBMET02710 | DBMET02709 | |
| 0.024 | 0.013 | 0.03 | Adenosine kinase inhibitor | 0.03 0.01 DBMET02709 0.02 0.016 DBMET02710 | DBMET02709 | |
| 0.124 | 0.114 | 0.177 | Neuropeptide Y1 antagonist | 0.175 0.034 DBMET02709 0.177 0.032 DBMET02710 | DBMET02710 | |
| 0.134 | 0.124 | 0.278 | DNA methyltransferase I inhibitor | 0.143 0.112 DBMET02707 0.234 0.054 DBMET02709 0.278 0.035 DBMET02710 | DBMET02710 | |
| 0.032 | 0.025 | 0.032 | Plasma kallikrein inhibitor | |||
| 0.016 | 0.009 | 0.022 | Purinergic P2Y1 agonist | 0.022 0.006 DBMET02709 0.021 0.006 DBMET02710 | DBMET02709 | |
| 0.052 | 0.045 | 0.052 | Tyrosine-protein kinase EMT inhibitor | |||
| 0.028 | 0.021 | 0.047 | CDK4/cyclin D3 inhibitor | 0.047 0.008 DBMET02709 0.035 0.013 DBMET02710 | DBMET02709 | |
| 0.142 | 0.135 | 0.276 | Death-associated protein kinase 3 inhibitor | 0.276 0.044 DBMET02709 0.182 0.086 DBMET02710 | DBMET02709 | |
| 0.051 | 0.044 | 0.068 | Pim-2 kinase inhibitor | 0.068 0.025 DBMET02709 0.05 0.045 DBMET02710 | DBMET02709 | |
| 0.123 | 0.117 | 0.245 | Adenylate cyclase stimulant | 0.126 0.111 DBMET02707 0.137 0.087 DBMET02708 0.217 0.008 DBMET02709 0.245 0.004 DBMET02710 | DBMET02710 | |
| 0.092 | 0.087 | 0.393 | Cystathionine beta-synthase inhibitor | 0.128 0.052 DBMET02707 0.117 0.06 DBMET02708 0.251 0.015 DBMET02709 0.393 0.005 DBMET02710 | DBMET02710 | |
| 0.069 | 0.064 | 0.367 | GABA aminotransferase inhibitor | 0.25 0.004 DBMET02709 0.367 0.003 DBMET02710 | DBMET02710 | |
| 0.061 | 0.056 | 0.078 | CDC7 inhibitor | 0.078 0.037 DBMET02709 | DBMET02709 | |
| 0.107 | 0.102 | 0.111 | Sodium channel blocker | 0.111 0.097 DBMET02709 | DBMET02709 | |
| 0.095 | 0.091 | 0.199 | Protein kinase (CK1) gamma 2 inhibitor | 0.199 0.032 DBMET02709 | DBMET02709 | |
| 0.058 | 0.054 | 0.072 | Histone deacetylase SIRT3 inhibitor | 0.072 0.025 DBMET02709 0.064 0.038 DBMET02710 | DBMET02709 | |
| 0.062 | 0.059 | 0.118 | Glutamate (mGluR7) antagonist | 0.118 0.005 DBMET02709 0.111 0.006 DBMET02710 | DBMET02709 | |
| 0.108 | 0.105 | 0.255 | Protein kinase (CK1) gamma inhibitor | 0.255 0.028 DBMET02709 0.111 0.1 DBMET02710 | DBMET02709 | |
| 0.253 | 0.25 | 0.52 | Caspase 9 stimulant | 0.452 0.082 DBMET02709 0.52 0.053 DBMET02710 | DBMET02710 | |
| 0.053 | 0.05 | 0.053 | CDK4/cyclin D inhibitor | |||
| 0.039 | 0.037 | 0.067 | GABA B receptor antagonist | 0.045 0.026 DBMET02707 0.067 0.009 DBMET02708 0.066 0.01 DBMET02709 0.057 0.014 DBMET02710 | DBMET02708 | |
| 0.017 | 0.016 | 0.022 | Methylmalonyl-CoA mutase inhibitor | 0.022 0.006 DBMET02709 0.02 0.008 DBMET02710 | DBMET02709 | |
| 0.04 | 0.04 | 0.07 | Adenosine deaminase inhibitor | 0.043 0.037 DBMET02708 0.07 0.014 DBMET02709 0.068 0.014 DBMET02710 | DBMET02709 | |
| 0.03 | 0.03 | 0.035 | Carboxypeptidase B inhibitor | 0.035 0.019 DBMET02709 0.032 0.025 DBMET02710 | DBMET02709 | |
| 0.102 | 0.103 | 0.233 | Cathepsin H inhibitor | 0.233 0.016 DBMET02709 0.196 0.023 DBMET02710 | DBMET02709 | |
| 0.054 | 0.055 | 0.096 | Adenosine A2 receptor antagonist | 0.096 0.028 DBMET02709 0.072 0.039 DBMET02710 | DBMET02709 | |
| 0.063 | 0.064 | 0.225 | Glutamate decarboxylase inhibitor | 0.156 0.012 DBMET02709 0.225 0.005 DBMET02710 0.212 0.006 DBMET02711 | DBMET02710 | |
| 0.068 | 0.069 | 0.072 | Fibroblast growth factor 3 antagonist | 0.072 0.062 DBMET02709 | DBMET02709 | |
| 0.02 | 0.022 | 0.026 | Isoleucine-tRNA ligase inhibitor | 0.026 0.009 DBMET02709 0.025 0.01 DBMET02710 | DBMET02709 | |
| 0.041 | 0.044 | 0.056 | Purinergic P2X4 antagonist | 0.052 0.022 DBMET02709 0.056 0.018 DBMET02710 | DBMET02710 | |
| 0.049 | 0.052 | 0.11 | Dihydroorotate oxidase inhibitor | 0.051 0.047 DBMET02708 0.101 0.005 DBMET02709 0.11 0.004 DBMET02710 | DBMET02710 | |
| 0.006 | 0.009 | 0.013 | DNA topoisomerase III inhibitor | 0.013 0.003 DBMET02709 0.009 0.004 DBMET02710 | DBMET02709 | |
| 0.023 | 0.027 | 0.04 | Complement factor 1s inhibitor | 0.04 0.004 DBMET02709 0.03 0.008 DBMET02710 | DBMET02709 | |
| 0.057 | 0.061 | 0.095 | Cyclin B3 inhibitor | 0.087 0.034 DBMET02709 0.095 0.031 DBMET02710 | DBMET02710 | |
| 0.025 | 0.029 | 0.032 | Hedgehog signaling activator | 0.032 0.01 DBMET02709 0.031 0.012 DBMET02710 | DBMET02709 | |
| 0.131 | 0.136 | 0.262 | DNA methylase inhibitor | 0.231 0.06 DBMET02709 0.262 0.042 DBMET02710 | DBMET02710 | |
| 0.014 | 0.02 | 0.019 | Histamine H4 receptor agonist | 0.019 0.012 DBMET02709 | DBMET02709 | |
| 0.058 | 0.063 | 0.1 | Transcription factor RelA inhibitor | 0.097 0.007 DBMET02709 0.1 0.006 DBMET02710 | DBMET02710 | |
| 0.035 | 0.041 | 0.056 | Thymidine kinase inhibitor | 0.056 0.015 DBMET02709 0.045 0.023 DBMET02710 | DBMET02709 | |
| 0.093 | 0.099 | 0.126 | TRKA antagonist | 0.126 0.063 DBMET02709 | DBMET02709 | |
| 0.002 | 0.009 | 0.005 | Reverse transcriptase (HBV) inhibitor | 0.005 0.003 DBMET02709 | DBMET02709 | |
| 0.015 | 0.022 | 0.023 | Complement factor D inhibitor | 0.023 0.006 DBMET02709 | DBMET02709 | |
| 0.018 | 0.025 | 0.023 | Toll-Like receptor 8 agonist | 0.023 0.009 DBMET02709 | DBMET02709 | |
| 0.111 | 0.118 | 0.322 | Mannose-6-phosphate isomerase inhibitor | 0.25 0.012 DBMET02709 0.241 0.014 DBMET02710 0.322 0.004 DBMET02711 | DBMET02711 | |
| 0.041 | 0.049 | 0.079 | Glucose-6-phosphate isomerase inhibitor | 0.079 0.009 DBMET02709 0.078 0.009 DBMET02710 | DBMET02709 | |
| 0.024 | 0.032 | 0.042 | Nicotinic alpha3beta4 receptor agonist | 0.042 0.009 DBMET02709 0.031 0.019 DBMET02710 | DBMET02709 | |
| 0.035 | 0.043 | 0.082 | Histamine H2 receptor agonist | 0.042 0.03 DBMET02708 0.082 0.007 DBMET02709 0.043 0.03 DBMET02710 | DBMET02709 | |
| 0.085 | 0.093 | 0.454 | Carbonic anhydrase XV inhibitor | 0.092 0.079 DBMET02707 0.115 0.05 DBMET02708 0.364 0.005 DBMET02709 0.454 0.004 DBMET02710 | DBMET02710 | |
| 0.029 | 0.038 | 0.05 | Potassium channel KCNQ activator | 0.05 0.016 DBMET02709 | DBMET02709 | |
| 0.029 | 0.038 | 0.05 | Delayed rectifier potassium channel activator | 0.05 0.016 DBMET02709 | DBMET02709 | |
| 0.158 | 0.167 | 0.212 | Calpain inhibitor | 0.212 0.102 DBMET02709 0.176 0.14 DBMET02710 0.211 0.103 DBMET02711 | DBMET02709 | |
| 0.049 | 0.059 | 0.075 | Botulinum neurotoxin type A inhibitor | 0.072 0.023 DBMET02709 0.075 0.02 DBMET02710 0.067 0.028 DBMET02711 | DBMET02710 | |
| 0.008 | 0.019 | 0.012 | Purine nucleoside phosphorylase inhibitor | 0.012 0.008 DBMET02709 0.011 0.009 DBMET02710 | DBMET02709 | |
| 0.154 | 0.166 | 0.318 | DNA damaging | 0.306 0.055 DBMET02709 0.318 0.05 DBMET02710 | DBMET02710 | |
| 0.079 | 0.09 | 0.226 | Protein kinase C zeta inhibitor | 0.088 0.069 DBMET02707 0.103 0.047 DBMET02708 0.175 0.015 DBMET02709 0.226 0.009 DBMET02710 | DBMET02710 | |
| 0.004 | 0.016 | 0.006 | CC chemokine 6 receptor agonist | 0.006 0.005 DBMET02709 | DBMET02709 | |
| 0.019 | 0.032 | 0.043 | Cyclin E2 inhibitor | 0.043 0.011 DBMET02709 0.035 0.015 DBMET02710 | DBMET02709 | |
| 0.031 | 0.044 | 0.157 | Dopamine D5 agonist | 0.042 0.025 DBMET02707 0.095 0.004 DBMET02709 0.157 0.003 DBMET02710 | DBMET02710 | |
| 0.007 | 0.019 | 0.01 | Purinergic P2Y2 agonist | 0.01 0.009 DBMET02709 | DBMET02709 | |
| 0.091 | 0.103 | 0.12 | Nav1.5 sodium channel blocker | 0.12 0.055 DBMET02709 | DBMET02709 | |
| 0.162 | 0.175 | 0.299 | 5 Hydroxytryptamine 1E antagonist | 0.185 0.148 DBMET02708 0.299 0.03 DBMET02709 0.291 0.035 DBMET02710 | DBMET02709 | |
| 0.062 | 0.075 | 0.103 | Adenosine A3 receptor antagonist | 0.103 0.025 DBMET02709 0.09 0.033 DBMET02710 | DBMET02709 | |
| 0.029 | 0.043 | 0.568 | Complement C3a chemotactic receptor antagonist | 0.463 0.002 DBMET02707 0.568 0.001 DBMET02708 | DBMET02708 | |
| 0.055 | 0.069 | 0.169 | Carbonic anhydrase VA inhibitor | 0.151 0.01 DBMET02709 0.169 0.008 DBMET02710 | DBMET02710 | |
| 0.013 | 0.029 | 0.017 | CC chemokine 9 receptor antagonist | 0.017 0.012 DBMET02709 | DBMET02709 | |
| 0.035 | 0.051 | 0.079 | Thymidylate synthase inhibitor | 0.045 0.035 DBMET02707 0.06 0.017 DBMET02708 0.079 0.008 DBMET02709 0.077 0.009 DBMET02710 | DBMET02709 | |
| 0.041 | 0.058 | 0.067 | Histamine agonist | 0.067 0.022 DBMET02709 | DBMET02709 | |
| 0.016 | 0.033 | 0.023 | Glutaminyl-peptide cyclotransferase inhibitor | 0.023 0.012 DBMET02709 | DBMET02709 | |
| 0.011 | 0.028 | 0.056 | Alpha 2a adrenoreceptor agonist | 0.056 0.004 DBMET02709 0.042 0.004 DBMET02710 | DBMET02709 | |
| 0.016 | 0.033 | 0.033 | Purinergic P2X agonist | 0.033 0.016 DBMET02709 0.028 0.018 DBMET02710 | DBMET02709 | |
| 0.021 | 0.039 | 0.031 | Thymidine phosphorylase inhibitor | 0.025 0.02 DBMET02707 0.031 0.011 DBMET02708 0.03 0.012 DBMET02709 0.026 0.018 DBMET02710 | DBMET02708 | |
| 0.008 | 0.027 | 0.018 | Adenosine A2a receptor agonist | 0.018 0.009 DBMET02709 0.018 0.009 DBMET02710 | DBMET02710 | |
| 0.047 | 0.067 | 0.067 | Cyclin A1 inhibitor | 0.067 0.026 DBMET02709 | DBMET02709 | |
| 0.048 | 0.068 | 0.082 | Sphingosine kinase inhibitor | 0.073 0.022 DBMET02709 0.082 0.015 DBMET02710 | DBMET02710 | |
| 0.01 | 0.03 | 0.014 | Cyclin D2 inhibitor | 0.014 0.007 DBMET02709 | DBMET02709 | |
| 0.029 | 0.05 | 0.054 | CDK5/p25 inhibitor | 0.052 0.02 DBMET02709 0.054 0.018 DBMET02710 | DBMET02710 | |
| 0.027 | 0.048 | 0.05 | Protein kinase (CK2) beta inhibitor | 0.047 0.008 DBMET02709 0.05 0.007 DBMET02710 | DBMET02710 | |
| 0.006 | 0.027 | 0.021 | Glutamate (mGluR6) agonist | 0.019 0.004 DBMET02709 0.021 0.004 DBMET02710 | DBMET02710 | |
| 0.01 | 0.031 | 0.019 | Adenosine A2 receptor agonist | 0.019 0.009 DBMET02709 0.019 0.009 DBMET02710 | DBMET02710 | |
| 0.039 | 0.062 | 0.067 | Toll-Like receptor 8 antagonist | 0.067 0.026 DBMET02709 | DBMET02709 | |
| 0.016 | 0.039 | 0.032 | Factor XIII inhibitor | 0.032 0.004 DBMET02709 0.019 0.018 DBMET02710 | DBMET02709 | |
| 0.039 | 0.063 | 0.107 | Adenosine A1 receptor antagonist | 0.107 0.022 DBMET02709 0.09 0.025 DBMET02710 | DBMET02709 | |
| 0.041 | 0.064 | 0.078 | CDK9/cyclin T1 inhibitor | 0.078 0.027 DBMET02709 | DBMET02709 | |
| 0.011 | 0.035 | 0.035 | Nicotinic acid receptor 1 antagonist | 0.023 0.007 DBMET02709 0.035 0.004 DBMET02710 | DBMET02710 | |
| 0.009 | 0.033 | 0.022 | Carbonic anhydrase X inhibitor | 0.022 0.007 DBMET02709 | DBMET02709 | |
| 0.009 | 0.033 | 0.022 | Carbonic anhydrase VIII inhibitor | 0.022 0.007 DBMET02709 | DBMET02709 | |
| 0.077 | 0.104 | 0.159 | Anabolic | 0.143 0.022 DBMET02709 0.159 0.014 DBMET02710 0.109 0.051 DBMET02711 | DBMET02710 | |
| 0.039 | 0.065 | 0.082 | Dopamine beta hydroxylase inhibitor | 0.069 0.008 DBMET02709 0.082 0.005 DBMET02710 | DBMET02710 | |
| 0.1 | 0.127 | 0.167 | Activin receptor-like kinase 2 inhibitor | 0.167 0.055 DBMET02709 0.136 0.079 DBMET02710 | DBMET02709 | |
| 0.075 | 0.102 | 0.18 | MAP kinase kinase 1 inhibitor | 0.105 0.05 DBMET02708 0.18 0.008 DBMET02709 0.176 0.009 DBMET02710 | DBMET02709 | |
| 0.054 | 0.081 | 0.123 | Aminopeptidase I inhibitor | 0.123 0.019 DBMET02709 0.117 0.02 DBMET02710 0.108 0.024 DBMET02711 | DBMET02709 | |
| 0.03 | 0.057 | 0.059 | Guanylate cyclase inhibitor | 0.059 0.012 DBMET02709 0.053 0.018 DBMET02710 | DBMET02709 | |
| 0.117 | 0.144 | 0.151 | MAP kinase 3 inhibitor | 0.151 0.067 DBMET02709 0.128 0.111 DBMET02710 | DBMET02709 | |
| 0.097 | 0.125 | 0.334 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.334 0.018 DBMET02709 0.22 0.044 DBMET02710 | DBMET02709 | |
| 0.082 | 0.11 | 0.137 | Glutamate (mGluR7) agonist | 0.137 0.017 DBMET02709 0.099 0.061 DBMET02710 | DBMET02709 | |
| 0.015 | 0.044 | 0.018 | Granulocyte colony stimulating factor receptor agonist | 0.018 0.013 DBMET02709 | DBMET02709 | |
| 0.013 | 0.043 | 0.05 | Glutamate (mGluR1a) agonist | 0.05 0.005 DBMET02709 0.032 0.008 DBMET02710 | DBMET02709 | |
| 0.072 | 0.102 | 0.16 | Estrogen-related receptor beta agonist | 0.078 0.073 DBMET02707 0.12 0.01 DBMET02709 0.16 0.004 DBMET02710 | DBMET02710 | |
| 0.028 | 0.058 | 0.045 | Tryptophan 5 hydroxylase inhibitor | 0.045 0.008 DBMET02709 0.036 0.024 DBMET02710 | DBMET02709 | |
| 0.046 | 0.076 | 0.191 | Carbonic anhydrase V inhibitor | 0.166 0.011 DBMET02709 0.191 0.008 DBMET02710 | DBMET02710 | |
| 0.082 | 0.113 | 0.131 | MAP kinase 13 inhibitor | 0.131 0.047 DBMET02709 | DBMET02709 | |
| 0.006 | 0.038 | 0.016 | Carbonic anhydrase XI inhibitor | 0.016 0.006 DBMET02709 | DBMET02709 | |
| 0.035 | 0.066 | 0.09 | Xanthine dehydrogenase inhibitor | 0.056 0.041 DBMET02707 0.09 0.019 DBMET02710 | DBMET02710 | |
| 0.11 | 0.142 | 0.223 | Arachidonic acid antagonist | 0.213 0.022 DBMET02709 0.223 0.015 DBMET02710 | DBMET02710 | |
| 0.042 | 0.074 | 0.06 | Glucosylceramidase inhibitor | 0.06 0.031 DBMET02709 0.056 0.037 DBMET02710 | DBMET02709 | |
| 0.078 | 0.11 | 0.237 | Adenylate cyclase inhibitor | 0.194 0.027 DBMET02709 0.237 0.02 DBMET02710 | DBMET02710 | |
| 0.109 | 0.142 | 0.245 | CDC-like kinase 4 inhibitor | 0.245 0.048 DBMET02709 | DBMET02709 | |
| 0.186 | 0.22 | 0.51 | Histamine release inhibitor | 0.465 0.043 DBMET02709 0.51 0.025 DBMET02710 | DBMET02710 | |
| 0.033 | 0.067 | 0.071 | Glutamate (mGluR4) antagonist | 0.071 0.01 DBMET02709 0.052 0.019 DBMET02710 | DBMET02709 | |
| 0.03 | 0.064 | 0.072 | Mannosidase inhibitor | 0.049 0.026 DBMET02707 0.057 0.019 DBMET02708 0.072 0.011 DBMET02709 0.072 0.011 DBMET02710 0.046 0.031 DBMET02711 | DBMET02710 | |
| 0.024 | 0.059 | 0.051 | Glutamate (mGluR3) agonist | 0.043 0.008 DBMET02709 0.051 0.005 DBMET02710 | DBMET02710 | |
| 0.012 | 0.046 | 0.029 | Imidazoline I1 receptor antagonist | 0.029 0.007 DBMET02709 | DBMET02709 | |
| 0.025 | 0.059 | 0.066 | Glutamate (mGluR3) antagonist | 0.066 0.007 DBMET02709 0.06 0.008 DBMET02710 | DBMET02709 | |
| 0.01 | 0.045 | 0.033 | Alpha 2c adrenoreceptor agonist | 0.033 0.004 DBMET02709 0.019 0.012 DBMET02710 | DBMET02709 | |
| 0.03 | 0.066 | 0.072 | Geranyltranstransferase inhibitor | 0.072 0.007 DBMET02709 0.066 0.009 DBMET02710 | DBMET02709 | |
| 0.046 | 0.082 | 0.119 | 5 Hydroxytryptamine 3 agonist | 0.119 0.009 DBMET02709 0.095 0.018 DBMET02710 | DBMET02709 | |
| 0.01 | 0.047 | 0.021 | Telomerase stimulant | 0.019 0.009 DBMET02709 0.021 0.007 DBMET02710 | DBMET02710 | |
| 0.09 | 0.127 | 0.107 | Sodium channel (voltage-gated) blocker | 0.107 0.101 DBMET02709 | DBMET02709 | |
| 0.052 | 0.089 | 0.079 | Rho-associated kinase I inhibitor | 0.079 0.047 DBMET02709 | DBMET02709 | |
| 0.069 | 0.107 | 0.235 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.235 0.011 DBMET02709 0.203 0.015 DBMET02710 | DBMET02709 | |
| 0.005 | 0.043 | 0.013 | Imidazoline I2 receptor antagonist | 0.013 0.005 DBMET02709 | DBMET02709 | |
| 0.08 | 0.118 | 0.172 | Protein kinase C gamma inhibitor | 0.097 0.082 DBMET02708 0.165 0.024 DBMET02709 0.172 0.021 DBMET02710 | DBMET02710 | |
| 0.026 | 0.065 | 0.042 | MAP3K5 inhibitor | 0.042 0.021 DBMET02709 | DBMET02709 | |
| 0.013 | 0.051 | 0.029 | Antibiotic Anthracycline-like | 0.024 0.005 DBMET02709 0.029 0.004 DBMET02710 | DBMET02710 | |
| 0.076 | 0.116 | 0.094 | Aurora-B kinase inhibitor | 0.094 0.09 DBMET02709 | DBMET02709 | |
| 0.015 | 0.055 | 0.036 | Nicotinic alpha4beta2 receptor agonist | 0.036 0.01 DBMET02709 | DBMET02709 | |
| 0.027 | 0.068 | 0.044 | Acid-sensing ion channel blocker | 0.044 0.023 DBMET02709 | DBMET02709 | |
| 0.049 | 0.089 | 0.119 | Ryanodine receptor antagonist | 0.103 0.004 DBMET02709 0.119 0.004 DBMET02710 | DBMET02710 | |
| 0.02 | 0.064 | 0.04 | MAP3K8 inhibitor | 0.04 0.007 DBMET02709 | DBMET02709 | |
| 0.02 | 0.065 | 0.03 | Glucosylceramidase stimulant | 0.03 0.013 DBMET02709 | DBMET02709 | |
| 0.065 | 0.11 | 0.162 | MAP kinase 9 inhibitor | 0.162 0.033 DBMET02709 | DBMET02709 | |
| 0.03 | 0.075 | 0.057 | Adenosine A2b receptor antagonist | 0.057 0.027 DBMET02709 | DBMET02709 | |
| 0.046 | 0.092 | 0.078 | Corticotropin releasing factor 2 receptor antagonist | 0.078 0.019 DBMET02709 | DBMET02709 | |
| 0.014 | 0.059 | 0.047 | Lysine carboxypeptidase inhibitor | 0.047 0.008 DBMET02709 0.046 0.008 DBMET02710 0.028 0.018 DBMET02711 | DBMET02709 | |
| 0.045 | 0.091 | 0.393 | Histidine decarboxylase inhibitor | 0.079 0.043 DBMET02707 0.075 0.046 DBMET02708 0.258 0.008 DBMET02709 0.393 0.004 DBMET02710 0.351 0.005 DBMET02711 | DBMET02710 | |
| 0.015 | 0.061 | 0.03 | Nicotinic acid receptor 2 antagonist | 0.03 0.013 DBMET02709 0.026 0.019 DBMET02710 | DBMET02709 | |
| 0.031 | 0.078 | 0.047 | mTOR inhibitor | 0.047 0.042 DBMET02709 | DBMET02709 | |
| 0.027 | 0.074 | 0.041 | Protein kinase (CK1) epsilon inhibitor | 0.041 0.024 DBMET02709 | DBMET02709 | |
| 0.048 | 0.096 | 0.114 | Potassium channel (ATP-sensitive) blocker | 0.114 0.01 DBMET02709 0.107 0.013 DBMET02710 | DBMET02709 | |
| 0.005 | 0.053 | 0.013 | Lysophosphatidic acid receptor 3 agonist | 0.013 0.01 DBMET02709 | DBMET02709 | |
| 0.018 | 0.066 | 0.036 | Thrombin receptor antagonist | 0.036 0.013 DBMET02709 | DBMET02709 | |
| 0.036 | 0.084 | 0.079 | Alpha-mannosidase inhibitor | 0.053 0.038 DBMET02707 0.06 0.027 DBMET02708 0.079 0.012 DBMET02709 0.079 0.012 DBMET02710 0.052 0.04 DBMET02711 | DBMET02710 | |
| 0.03 | 0.08 | 0.06 | Kainate receptor agonist | 0.06 0.007 DBMET02709 0.057 0.008 DBMET02710 | DBMET02709 | |
| 0.03 | 0.08 | 0.1 | Adenylate cyclase 1 inhibitor | 0.1 0.004 DBMET02709 0.095 0.005 DBMET02710 | DBMET02709 | |
| 0.008 | 0.058 | 0.018 | Thromboxane A2 agonist | 0.018 0.008 DBMET02709 0.015 0.012 DBMET02710 | DBMET02709 | |
| 0.011 | 0.062 | 0.037 | Kynurenine 3 monooxygenase inhibitor | 0.037 0.011 DBMET02709 0.026 0.019 DBMET02710 | DBMET02709 | |
| 0.081 | 0.132 | 0.219 | Lck kinase inhibitor | 0.219 0.033 DBMET02709 0.13 0.078 DBMET02710 | DBMET02709 | |
| 0.079 | 0.131 | 0.156 | Protein kinase (CK1) inhibitor | 0.156 0.063 DBMET02709 | DBMET02709 | |
| 0.037 | 0.091 | 0.084 | Carbonic anhydrase stimulant | 0.084 0.024 DBMET02709 0.065 0.035 DBMET02710 | DBMET02709 | |
| 0.032 | 0.085 | 0.067 | Glutamate (mGluR group III) antagonist | 0.067 0.01 DBMET02709 0.054 0.017 DBMET02710 | DBMET02709 | |
| 0.006 | 0.059 | 0.014 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.014 0.008 DBMET02709 | DBMET02709 | |
| 0.126 | 0.18 | 0.334 | Immunostimulant | 0.265 0.09 DBMET02709 0.318 0.074 DBMET02710 0.334 0.069 DBMET02711 | DBMET02711 | |
| 0.095 | 0.149 | 0.173 | Diuretic | 0.173 0.059 DBMET02709 0.153 0.075 DBMET02710 0.124 0.1 DBMET02711 | DBMET02709 | |
| 0.025 | 0.08 | 0.211 | Carbonic anhydrase VB inhibitor | 0.183 0.006 DBMET02709 0.211 0.005 DBMET02710 | DBMET02710 | |
| 0.075 | 0.13 | 0.199 | Alkylator | 0.179 0.033 DBMET02709 0.199 0.027 DBMET02710 | DBMET02710 | |
| 0.006 | 0.062 | 0.03 | NMDA receptor phencyclidine site antagonist | 0.028 0.005 DBMET02709 0.03 0.004 DBMET02710 | DBMET02710 | |
| 0.019 | 0.076 | 0.03 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.03 0.011 DBMET02709 0.026 0.022 DBMET02710 | DBMET02709 | |
| 0.082 | 0.139 | 0.246 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.246 0.033 DBMET02709 | DBMET02709 | |
| 0.052 | 0.109 | 0.088 | Bcr-Abl kinase inhibitor | 0.088 0.054 DBMET02709 0.085 0.057 DBMET02710 | DBMET02709 | |
| 0.018 | 0.075 | 0.037 | 5 Hydroxytryptamine 6 agonist | 0.037 0.009 DBMET02709 | DBMET02709 | |
| 0.055 | 0.112 | 0.254 | Potassium channel (Ca-activated) activator | 0.085 0.069 DBMET02707 0.188 0.017 DBMET02709 0.254 0.008 DBMET02710 | DBMET02710 | |
| 0.11 | 0.168 | 0.242 | Tumour necrosis factor antagonist | 0.242 0.033 DBMET02709 0.234 0.036 DBMET02710 | DBMET02709 | |
| 0.012 | 0.071 | 0.027 | Neuraminidase (Influenza B) inhibitor | 0.026 0.007 DBMET02709 0.027 0.006 DBMET02710 | DBMET02710 | |
| 0.014 | 0.073 | 0.026 | Lysophosphatidic acid receptor 1 agonist | 0.026 0.015 DBMET02709 | DBMET02709 | |
| 0.013 | 0.073 | 0.024 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.024 0.008 DBMET02709 0.019 0.018 DBMET02710 | DBMET02709 | |
| 0.019 | 0.079 | 0.061 | Estrogen-related receptor gamma antagonist | 0.047 0.004 DBMET02709 0.061 0.002 DBMET02710 | DBMET02710 | |
| 0.069 | 0.129 | 0.158 | Xanthine oxidase inhibitor | 0.085 0.081 DBMET02707 0.086 0.078 DBMET02709 0.158 0.032 DBMET02710 0.091 0.069 DBMET02711 | DBMET02710 | |
| 0.034 | 0.094 | 0.057 | Heme oxygenase inhibitor | 0.057 0.008 DBMET02709 0.049 0.015 DBMET02710 | DBMET02709 | |
| 0.044 | 0.104 | 0.063 | CDK2/cyclin E2 inhibitor | 0.063 0.058 DBMET02709 | DBMET02709 | |
| 0.028 | 0.089 | 0.043 | Glutamate (mGluR5) agonist | 0.043 0.037 DBMET02709 | DBMET02709 | |
| 0.016 | 0.078 | 0.047 | Integrin alpha2beta1 antagonist | 0.047 0.005 DBMET02709 0.033 0.01 DBMET02710 | DBMET02709 | |
| 0.073 | 0.136 | 0.11 | Nav1.4 sodium channel blocker | 0.11 0.062 DBMET02710 | DBMET02710 | |
| 0.026 | 0.09 | 0.071 | Nerve growth factor antagonist | 0.071 0.005 DBMET02709 0.056 0.013 DBMET02710 | DBMET02709 | |
| 0.032 | 0.097 | 0.217 | NMDA 2C receptor antagonist | 0.151 0.007 DBMET02709 0.217 0.005 DBMET02710 | DBMET02710 | |
| 0.025 | 0.09 | 0.062 | Potassium channel Kv1.1 blocker | 0.062 0.008 DBMET02709 0.041 0.021 DBMET02710 | DBMET02709 | |
| 0.049 | 0.115 | 0.11 | Ornithine decarboxylase inhibitor | 0.102 0.042 DBMET02709 0.11 0.034 DBMET02710 | DBMET02710 | |
| 0.019 | 0.085 | 0.049 | Purinergic P2Y antagonist | 0.049 0.027 DBMET02709 0.043 0.033 DBMET02710 | DBMET02709 | |
| 0.033 | 0.099 | 0.16 | Topoisomerase II beta inhibitor | 0.12 0.007 DBMET02709 0.16 0.005 DBMET02710 | DBMET02710 | |
| 0.015 | 0.081 | 0.03 | Vanilloid 2 agonist | 0.029 0.011 DBMET02709 0.03 0.01 DBMET02710 | DBMET02710 | |
| 0.086 | 0.153 | 0.281 | Protein kinase C nu inhibitor | 0.118 0.095 DBMET02708 0.281 0.028 DBMET02709 0.14 0.075 DBMET02710 | DBMET02709 | |
| 0.031 | 0.098 | 0.053 | EphB4 antagonist | 0.053 0.046 DBMET02709 | DBMET02709 | |
| 0.123 | 0.191 | 0.421 | Interleukin agonist | 0.215 0.107 DBMET02708 0.421 0.016 DBMET02709 0.409 0.017 DBMET02710 | DBMET02709 | |
| 0.015 | 0.085 | 0.033 | Glutamate (mGluR1) agonist | 0.033 0.008 DBMET02709 0.027 0.013 DBMET02710 | DBMET02709 | |
| 0.174 | 0.245 | 0.257 | DNA polymerase beta inhibitor | 0.244 0.196 DBMET02709 0.257 0.188 DBMET02710 | DBMET02710 | |
| 0.049 | 0.12 | 0.152 | Macrophage migration inhibitory factor inhibitor | 0.075 0.058 DBMET02709 0.152 0.015 DBMET02710 | DBMET02710 | |
| 0.019 | 0.091 | 0.064 | Oxytocin agonist | 0.055 0.021 DBMET02709 0.064 0.014 DBMET02710 | DBMET02710 | |
| 0.009 | 0.081 | 0.055 | Arginase inhibitor | 0.052 0.014 DBMET02709 0.055 0.012 DBMET02710 | DBMET02710 | |
| 0.045 | 0.118 | 0.146 | CYP2A6 inhibitor | 0.146 0.018 DBMET02709 0.087 0.043 DBMET02710 | DBMET02709 | |
| 0.033 | 0.106 | 0.055 | Squalene epoxidase inhibitor | 0.053 0.029 DBMET02709 0.055 0.027 DBMET02710 | DBMET02710 | |
| 0.144 | 0.217 | 0.385 | 12-Lipoxygenase inhibitor | 0.183 0.17 DBMET02707 0.272 0.096 DBMET02709 0.385 0.043 DBMET02710 0.306 0.076 DBMET02711 | DBMET02710 | |
| 0.033 | 0.106 | 0.054 | Cyclin-dependent kinase 6 inhibitor | 0.054 0.048 DBMET02709 | DBMET02709 | |
| 0.01 | 0.084 | 0.044 | Estrogen-related receptor gamma agonist | 0.026 0.005 DBMET02709 0.044 0.003 DBMET02710 | DBMET02710 | |
| 0.022 | 0.097 | 0.064 | Glutamate (mGluR1a) antagonist | 0.064 0.013 DBMET02709 | DBMET02709 | |
| 0.01 | 0.086 | 0.02 | Alpha 2b adrenoreceptor agonist | 0.02 0.01 DBMET02709 | DBMET02709 | |
| 0.076 | 0.152 | 0.139 | TRPA1 agonist | 0.124 0.053 DBMET02709 0.139 0.039 DBMET02710 | DBMET02710 | |
| 0.056 | 0.132 | 0.12 | Histamine H2 receptor antagonist | 0.12 0.021 DBMET02709 0.091 0.045 DBMET02710 | DBMET02709 | |
| 0.08 | 0.157 | 0.168 | Nav1.2 sodium channel blocker | 0.168 0.047 DBMET02709 0.127 0.075 DBMET02710 | DBMET02709 | |
| 0.034 | 0.113 | 0.095 | MAP kinase 11 inhibitor | 0.095 0.039 DBMET02709 | DBMET02709 | |
| 0.049 | 0.128 | 0.16 | Glycine receptor agonist | 0.16 0.006 DBMET02709 0.159 0.006 DBMET02710 | DBMET02709 | |
| 0.077 | 0.157 | 0.181 | Acetylcholine release stimulant | 0.181 0.005 DBMET02709 0.143 0.021 DBMET02710 | DBMET02709 | |
| 0.017 | 0.097 | 0.054 | Inosine monophosphate dehydrogenase inhibitor | 0.054 0.013 DBMET02709 0.052 0.014 DBMET02710 | DBMET02709 | |
| 0.086 | 0.166 | 0.375 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.125 0.11 DBMET02708 0.375 0.022 DBMET02709 0.204 0.062 DBMET02710 | DBMET02709 | |
| 0.021 | 0.101 | 0.054 | Membrane dipeptidase inhibitor | 0.054 0.013 DBMET02709 0.042 0.023 DBMET02710 | DBMET02709 | |
| 0.038 | 0.121 | 0.102 | Na+ K+ transporting ATPase inhibitor | 0.095 0.036 DBMET02709 0.102 0.03 DBMET02710 | DBMET02710 | |
| 0.065 | 0.148 | 0.11 | CC chemokine 5 receptor agonist | 0.101 0.02 DBMET02709 0.11 0.013 DBMET02710 | DBMET02710 | |
| 0.019 | 0.102 | 0.043 | Glutamate (mGluR group I) agonist | 0.043 0.039 DBMET02709 | DBMET02709 | |
| 0.032 | 0.116 | 0.143 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.087 0.021 DBMET02709 0.143 0.008 DBMET02710 | DBMET02710 | |
| 0.067 | 0.151 | 0.238 | Mucolytic | 0.156 0.029 DBMET02709 0.183 0.018 DBMET02710 0.238 0.008 DBMET02711 | DBMET02711 | |
| 0.028 | 0.112 | 0.146 | NMDA receptor glycine site agonist | 0.146 0.005 DBMET02709 0.128 0.007 DBMET02710 | DBMET02709 | |
| 0.133 | 0.219 | 0.308 | Prostaglandin dehydrogenase inhibitor | 0.213 0.149 DBMET02707 0.276 0.114 DBMET02709 0.308 0.098 DBMET02710 | DBMET02710 | |
| 0.074 | 0.16 | 0.169 | Photosensitizer | 0.166 0.023 DBMET02709 0.169 0.022 DBMET02710 | DBMET02710 | |
| 0.032 | 0.119 | 0.101 | Cyclin D1 inhibitor | 0.101 0.008 DBMET02709 0.097 0.009 DBMET02710 | DBMET02709 | |
| 0.027 | 0.113 | 0.05 | Diacylglycerol O-acyltransferase inhibitor | 0.05 0.036 DBMET02709 | DBMET02709 | |
| 0.02 | 0.107 | 0.062 | Integrin alpha2 antagonist | 0.062 0.007 DBMET02709 0.045 0.015 DBMET02710 | DBMET02709 | |
| 0.008 | 0.096 | 0.022 | Factor IX inhibitor | 0.022 0.01 DBMET02708 | DBMET02708 | |
| 0.055 | 0.143 | 0.1 | Granulocyte macrophage colony stimulating factor antagonist | 0.1 0.071 DBMET02709 | DBMET02709 | |
| 0.025 | 0.114 | 0.079 | Beta 2 adrenoreceptor antagonist | 0.057 0.028 DBMET02709 0.079 0.012 DBMET02710 | DBMET02710 | |
| 0.037 | 0.127 | 0.165 | NMDA receptor agonist | 0.165 0.006 DBMET02709 0.144 0.009 DBMET02710 0.065 0.041 DBMET02711 | DBMET02709 | |
| 0.026 | 0.117 | 0.084 | Potassium channel small-conductance Ca-activated blocker | 0.084 0.009 DBMET02709 | DBMET02709 | |
| 0.003 | 0.093 | 0.01 | Angiotensin AT2 receptor agonist | 0.01 0.008 DBMET02709 | DBMET02709 | |
| 0.018 | 0.109 | 0.055 | Glycine transporter 2 inhibitor | 0.055 0.028 DBMET02710 | DBMET02710 | |
| 0.006 | 0.098 | 0.016 | Nicotinic alpha4 receptor agonist | 0.016 0.012 DBMET02709 | DBMET02709 | |
| 0.048 | 0.141 | 0.079 | Prolactin release inhibitor | 0.079 0.011 DBMET02709 0.076 0.014 DBMET02710 | DBMET02709 | |
| 0.008 | 0.101 | 0.039 | Uridine phosphorylase inhibitor | 0.039 0.012 DBMET02709 0.034 0.015 DBMET02710 | DBMET02709 | |
| 0.039 | 0.131 | 0.12 | Nicotinic alpha4beta2 receptor antagonist | 0.088 0.042 DBMET02708 0.12 0.018 DBMET02709 0.084 0.046 DBMET02710 | DBMET02709 | |
| 0.025 | 0.117 | 0.072 | Lysophosphatidic acid 3 receptor antagonist | 0.072 0.013 DBMET02709 0.063 0.02 DBMET02710 | DBMET02709 | |
| 0.018 | 0.111 | 0.066 | Phosphorylase inhibitor | 0.061 0.024 DBMET02709 0.066 0.022 DBMET02710 | DBMET02710 | |
| 0.023 | 0.117 | 0.046 | Adenosine uptake inhibitor | 0.046 0.006 DBMET02709 0.035 0.023 DBMET02710 | DBMET02709 | |
| 0.113 | 0.207 | 0.408 | Neurotrophic factor enhancer | 0.321 0.013 DBMET02709 0.408 0.005 DBMET02710 | DBMET02710 | |
| 0.012 | 0.106 | 0.042 | Methionyl aminopeptidase 1 inhibitor | 0.042 0.01 DBMET02709 0.03 0.025 DBMET02710 | DBMET02709 | |
| 0.04 | 0.135 | 0.067 | Thrombin inhibitor | 0.067 0.059 DBMET02709 | DBMET02709 | |
| 0.04 | 0.136 | 0.104 | Phospholipase D inhibitor | 0.104 0.013 DBMET02709 0.08 0.034 DBMET02710 | DBMET02709 | |
| 0.017 | 0.113 | 0.08 | Carbonic anhydrase I inhibitor | 0.08 0.025 DBMET02709 0.076 0.027 DBMET02710 | DBMET02709 | |
| 0.014 | 0.11 | 0.032 | Calcitonin receptor agonist | 0.029 0.028 DBMET02709 0.032 0.025 DBMET02710 | DBMET02710 | |
| 0.047 | 0.144 | 0.386 | Carbonic anhydrase VI inhibitor | 0.265 0.008 DBMET02709 0.386 0.004 DBMET02710 | DBMET02710 | |
| 0.023 | 0.12 | 0.047 | 5 Hydroxytryptamine 2B agonist | 0.047 0.015 DBMET02709 | DBMET02709 | |
| 0.039 | 0.137 | 0.079 | Protein kinase B beta inhibitor | 0.079 0.044 DBMET02709 | DBMET02709 | |
| 0.044 | 0.142 | 0.064 | Trypsin inhibitor | 0.064 0.041 DBMET02709 | DBMET02709 | |
| 0.012 | 0.11 | 0.087 | Carbonic anhydrase IX inhibitor | 0.087 0.024 DBMET02709 0.085 0.024 DBMET02710 | DBMET02709 | |
| 0.013 | 0.111 | 0.047 | Retinoid X alpha receptor agonist | 0.047 0.016 DBMET02709 0.039 0.02 DBMET02710 | DBMET02709 | |
| 0.025 | 0.124 | 0.079 | GABA receptor antagonist | 0.079 0.022 DBMET02709 0.061 0.031 DBMET02710 | DBMET02709 | |
| 0.066 | 0.166 | 0.13 | Cyclin-dependent kinase 7 inhibitor | 0.13 0.076 DBMET02709 | DBMET02709 | |
| 0.012 | 0.112 | 0.055 | Nicotinic acid receptor agonist | 0.037 0.023 DBMET02709 0.055 0.013 DBMET02710 | DBMET02710 | |
| 0.029 | 0.13 | 0.119 | Alpha 2 adrenoreceptor agonist | 0.119 0.01 DBMET02709 0.098 0.015 DBMET02710 | DBMET02709 | |
| 0.013 | 0.114 | 0.031 | Acid ceramidase inhibitor | 0.031 0.008 DBMET02709 | DBMET02709 | |
| 0.016 | 0.117 | 0.081 | Carbonic anhydrase II inhibitor | 0.08 0.025 DBMET02709 0.081 0.025 DBMET02710 | DBMET02710 | |
| 0.029 | 0.131 | 0.123 | Factor IXa inhibitor | 0.094 0.011 DBMET02707 0.123 0.005 DBMET02708 0.07 0.02 DBMET02709 0.066 0.022 DBMET02710 | DBMET02708 | |
| 0.012 | 0.114 | 0.084 | Carbonic anhydrase XII inhibitor | 0.075 0.027 DBMET02709 0.084 0.024 DBMET02710 | DBMET02710 | |
| 0.099 | 0.202 | 0.174 | Sphingosine 1-phosphate receptor 5 antagonist | 0.174 0.03 DBMET02709 0.171 0.033 DBMET02710 | DBMET02709 | |
| 0.008 | 0.111 | 0.031 | CXC chemokine 2 receptor antagonist | 0.026 0.019 DBMET02709 0.031 0.013 DBMET02710 | DBMET02710 | |
| 0.013 | 0.116 | 0.028 | 5 Hydroxytryptamine 4 agonist | 0.028 0.009 DBMET02709 | DBMET02709 | |
| 0.006 | 0.109 | 0.028 | Inosine monophosphate dehydrogenase 2 inhibitor | 0.028 0.009 DBMET02709 0.028 0.008 DBMET02710 | DBMET02710 | |
| 0.011 | 0.117 | 0.091 | Kainate receptor antagonist | 0.091 0.008 DBMET02709 0.079 0.01 DBMET02710 | DBMET02709 | |
| 0.013 | 0.119 | 0.065 | Histone deacetylase class I inhibitor | 0.065 0.014 DBMET02709 0.039 0.027 DBMET02710 | DBMET02709 | |
| 0.03 | 0.136 | 0.058 | Heparanase inhibitor | 0.058 0.026 DBMET02709 0.058 0.027 DBMET02710 | DBMET02710 | |
| 0.024 | 0.13 | 0.076 | GABA A receptor antagonist | 0.076 0.023 DBMET02709 0.057 0.033 DBMET02710 | DBMET02709 | |
| 0.02 | 0.127 | 0.078 | AMPA 4 receptor antagonist | 0.078 0.007 DBMET02709 0.077 0.007 DBMET02710 | DBMET02709 | |
| 0.07 | 0.176 | 0.269 | Aldehyde dehydrogenase inhibitor | 0.185 0.032 DBMET02709 0.269 0.015 DBMET02710 | DBMET02710 | |
| 0.007 | 0.114 | 0.035 | NMDA receptor glycine site antagonist | 0.035 0.01 DBMET02709 0.035 0.01 DBMET02710 | DBMET02710 | |
| 0.101 | 0.209 | 0.282 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.282 0.048 DBMET02709 0.146 0.115 DBMET02710 | DBMET02709 | |
| 0.011 | 0.12 | 0.028 | Glutamate (mGluR2) antagonist | 0.028 0.024 DBMET02709 | DBMET02709 | |
| 0.043 | 0.153 | 0.075 | Insulin like growth factor 1 antagonist | 0.075 0.068 DBMET02709 | DBMET02709 | |
| 0.04 | 0.15 | 0.058 | Leukotriene C antagonist | 0.055 0.042 DBMET02709 0.058 0.034 DBMET02710 | DBMET02710 | |
| 0.057 | 0.168 | 0.166 | Lanosterol 14 alpha demethylase inhibitor | 0.166 0.007 DBMET02709 0.16 0.009 DBMET02710 | DBMET02709 | |
| 0.032 | 0.142 | 0.101 | Histone deacetylase inhibitor | 0.101 0.018 DBMET02709 0.072 0.038 DBMET02710 | DBMET02709 | |
| 0.045 | 0.156 | 0.082 | Beta 2 adrenoreceptor agonist | 0.067 0.025 DBMET02709 0.082 0.008 DBMET02710 | DBMET02710 | |
| 0.126 | 0.238 | 0.311 | Lipoxygenase inhibitor | 0.2 0.14 DBMET02709 0.311 0.066 DBMET02710 0.176 0.168 DBMET02711 | DBMET02710 | |
| 0.015 | 0.128 | 0.038 | Glutamate (mGluR group II) antagonist | 0.038 0.027 DBMET02709 | DBMET02709 | |
| 0.074 | 0.187 | 0.135 | Histone deacetylase SIRT1 inhibitor | 0.125 0.085 DBMET02709 0.135 0.075 DBMET02710 | DBMET02710 | |
| 0.026 | 0.14 | 0.121 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.068 0.023 DBMET02709 0.121 0.007 DBMET02710 | DBMET02710 | |
| 0.07 | 0.184 | 0.181 | Src kinase inhibitor | 0.181 0.064 DBMET02709 0.131 0.098 DBMET02710 | DBMET02709 | |
| 0.053 | 0.168 | 0.101 | Insulin receptor antagonist | 0.101 0.06 DBMET02709 | DBMET02709 | |
| 0.026 | 0.14 | 0.037 | Leukotriene C4 antagonist | 0.037 0.033 DBMET02710 | DBMET02710 | |
| 0.032 | 0.148 | 0.091 | Neuraminidase (influenza) inhibitor | 0.091 0.019 DBMET02710 | DBMET02710 | |
| 0.048 | 0.165 | 0.13 | Sphingomyelinase inhibitor | 0.13 0.034 DBMET02709 0.11 0.049 DBMET02710 | DBMET02709 | |
| 0.041 | 0.157 | 0.08 | Insulin growth factor antagonist | 0.08 0.067 DBMET02709 | DBMET02709 | |
| 0.021 | 0.139 | 0.05 | Cyclin B2 inhibitor | 0.05 0.046 DBMET02710 | DBMET02710 | |
| 0.077 | 0.195 | 0.187 | Mcl-1 antagonist | 0.145 0.095 DBMET02707 0.187 0.063 DBMET02710 | DBMET02710 | |
| 0.008 | 0.125 | 0.025 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.025 0.022 DBMET02709 | DBMET02709 | |
| 0.026 | 0.145 | 0.042 | Dipeptidyl peptidase IV inhibitor | 0.042 0.038 DBMET02709 | DBMET02709 | |
| 0.02 | 0.14 | 0.047 | Sphingosine kinase 1 inhibitor | 0.046 0.021 DBMET02709 0.047 0.019 DBMET02710 | DBMET02710 | |
| 0.004 | 0.124 | 0.027 | Ileal bile acid transport inhibitor | 0.02 0.009 DBMET02709 0.027 0.005 DBMET02710 | DBMET02710 | |
| 0.028 | 0.149 | 0.113 | Sphingosine 1-phosphate receptor 4 agonist | 0.113 0.019 DBMET02709 0.104 0.023 DBMET02710 | DBMET02709 | |
| 0.144 | 0.266 | 0.334 | Insulysin inhibitor | 0.221 0.128 DBMET02707 0.242 0.104 DBMET02708 0.321 0.047 DBMET02709 0.334 0.04 DBMET02710 0.321 0.047 DBMET02711 | DBMET02710 | |
| 0.011 | 0.133 | 0.062 | Vascular adhesion protein 1 inhibitor | 0.062 0.009 DBMET02709 | DBMET02709 | |
| 0.027 | 0.149 | 0.042 | CF transmembrane conductance regulator antagonist | 0.042 0.019 DBMET02710 | DBMET02710 | |
| 0.049 | 0.171 | 0.15 | MAP kinase 8 inhibitor | 0.15 0.03 DBMET02709 | DBMET02709 | |
| 0.047 | 0.17 | 0.189 | Falcipain 3 inhibitor | 0.189 0.021 DBMET02709 0.174 0.026 DBMET02710 | DBMET02709 | |
| 0.017 | 0.14 | 0.098 | Carbonic anhydrase inhibitor | 0.092 0.03 DBMET02709 0.098 0.028 DBMET02710 | DBMET02710 | |
| 0.045 | 0.167 | 0.18 | Keratolytic | 0.103 0.029 DBMET02709 0.18 0.01 DBMET02710 | DBMET02710 | |
| 0.028 | 0.152 | 0.108 | HIV-1 integrase (3'-Processing) inhibitor | 0.108 0.023 DBMET02710 0.06 0.047 DBMET02711 | DBMET02710 | |
| 0.046 | 0.17 | 0.084 | Calcium channel P-type blocker | 0.084 0.012 DBMET02709 0.07 0.028 DBMET02710 | DBMET02709 | |
| 0.044 | 0.168 | 0.247 | Alcohol dehydrogenase inhibitor | 0.139 0.024 DBMET02709 0.227 0.01 DBMET02710 0.247 0.008 DBMET02711 | DBMET02711 | |
| 0.013 | 0.137 | 0.137 | NMDA receptor subunit 3A antagonist | 0.08 0.012 DBMET02709 0.137 0.005 DBMET02710 | DBMET02710 | |
| 0.06 | 0.184 | 0.116 | TRKB antagonist | 0.116 0.078 DBMET02709 | DBMET02709 | |
| 0.015 | 0.14 | 0.032 | Dipeptidyl peptidase II inhibitor | 0.032 0.023 DBMET02709 | DBMET02709 | |
| 0.113 | 0.238 | 0.303 | Cyclic AMP phosphodiesterase inhibitor | 0.293 0.045 DBMET02709 0.303 0.041 DBMET02710 | DBMET02710 | |
| 0.035 | 0.16 | 0.084 | TIE-2 antagonist | 0.084 0.053 DBMET02709 | DBMET02709 | |
| 0.014 | 0.14 | 0.172 | NMDA 2A receptor antagonist | 0.12 0.009 DBMET02709 0.172 0.005 DBMET02710 | DBMET02710 | |
| 0.024 | 0.152 | 0.072 | 5 Hydroxytryptamine 2A agonist | 0.072 0.035 DBMET02709 0.067 0.04 DBMET02710 | DBMET02709 | |
| 0.039 | 0.166 | 0.28 | Monophenol monooxygenase inhibitor | 0.137 0.052 DBMET02709 0.28 0.02 DBMET02710 0.198 0.034 DBMET02711 | DBMET02710 | |
| 0.14 | 0.268 | 0.251 | Antithrombotic | 0.229 0.145 DBMET02709 0.251 0.125 DBMET02710 | DBMET02710 | |
| 0.033 | 0.162 | 0.213 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.147 0.019 DBMET02709 0.213 0.008 DBMET02710 0.078 0.053 DBMET02711 | DBMET02710 | |
| 0.128 | 0.257 | 0.212 | MAP kinase kinase 5 inhibitor | 0.212 0.021 DBMET02709 0.156 0.128 DBMET02710 | DBMET02709 | |
| 0.077 | 0.206 | 0.2 | Cell wall synthesis inhibitor | 0.184 0.038 DBMET02709 0.2 0.03 DBMET02710 | DBMET02710 | |
| 0.035 | 0.164 | 0.085 | TIE antagonist | 0.085 0.055 DBMET02709 | DBMET02709 | |
| 0.015 | 0.145 | 0.049 | GABA uptake inhibitor | 0.049 0.016 DBMET02709 0.04 0.026 DBMET02710 | DBMET02709 | |
| 0.026 | 0.156 | 0.061 | Potassium channel (ATP-sensitive) activator | 0.061 0.015 DBMET02709 0.047 0.037 DBMET02710 | DBMET02709 | |
| 0.027 | 0.158 | 0.064 | Potassium channel (Inward rectifier) activator | 0.064 0.016 DBMET02709 0.049 0.038 DBMET02710 | DBMET02709 | |
| 0.058 | 0.189 | 0.2 | Nav1.6 sodium channel blocker | 0.13 0.081 DBMET02708 0.2 0.019 DBMET02709 0.168 0.037 DBMET02710 | DBMET02709 | |
| 0.04 | 0.173 | 0.075 | Epidermal growth factor antagonist | 0.075 0.074 DBMET02709 | DBMET02709 | |
| 0.047 | 0.18 | 0.226 | Expectorant | 0.146 0.037 DBMET02709 0.189 0.023 DBMET02710 0.226 0.016 DBMET02711 | DBMET02711 | |
| 0.008 | 0.142 | 0.023 | Protease (Human cytomegalovirus) inhibitor | 0.023 0.014 DBMET02709 | DBMET02709 | |
| 0.019 | 0.153 | 0.044 | Histone deacetylase 9 inhibitor | 0.044 0.021 DBMET02709 | DBMET02709 | |
| 0.008 | 0.143 | 0.039 | Retinoid X receptor agonist | 0.039 0.023 DBMET02709 0.033 0.027 DBMET02710 | DBMET02709 | |
| 0.008 | 0.144 | 0.027 | Beta 1 adrenoreceptor agonist | 0.027 0.01 DBMET02710 | DBMET02710 | |
| 0.006 | 0.143 | 0.073 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.022 0.016 DBMET02709 0.073 0.005 DBMET02710 | DBMET02710 | |
| 0.109 | 0.246 | 0.221 | Neurotensin receptor agonist | 0.144 0.117 DBMET02707 0.144 0.117 DBMET02708 0.188 0.042 DBMET02709 0.221 0.027 DBMET02710 | DBMET02710 | |
| 0.019 | 0.156 | 0.049 | Dihydroorotase inhibitor | 0.049 0.026 DBMET02709 | DBMET02709 | |
| 0.033 | 0.17 | 0.081 | Potassium channel intermediate-conductance Ca-activated blocker | 0.081 0.017 DBMET02709 | DBMET02709 | |
| 0.092 | 0.229 | 0.233 | Interferon gamma antagonist | 0.179 0.051 DBMET02709 0.233 0.032 DBMET02710 | DBMET02710 | |
| 0.087 | 0.225 | 0.225 | Insulin sensitizer | 0.205 0.069 DBMET02709 0.225 0.051 DBMET02710 | DBMET02710 | |
| 0.047 | 0.186 | 0.092 | Aminoacyl-tRNA synthetase inhibitor | 0.092 0.056 DBMET02710 | DBMET02710 | |
| 0.011 | 0.152 | 0.034 | Epoxide hydrolase 1 inhibitor | 0.034 0.017 DBMET02709 | DBMET02709 | |
| 0.059 | 0.2 | 0.142 | Microtubule formation inhibitor | 0.142 0.042 DBMET02709 0.141 0.043 DBMET02710 | DBMET02709 | |
| 0.095 | 0.237 | 0.239 | 3C-like protease (Human coronavirus) inhibitor | 0.239 0.032 DBMET02709 0.183 0.063 DBMET02710 | DBMET02709 | |
| 0.008 | 0.15 | 0.05 | AMPA 3 receptor antagonist | 0.05 0.009 DBMET02709 0.045 0.011 DBMET02710 | DBMET02709 | |
| 0.01 | 0.153 | 0.085 | Carbonic anhydrase VII inhibitor | 0.059 0.02 DBMET02709 0.085 0.012 DBMET02710 | DBMET02710 | |
| 0.036 | 0.178 | 0.074 | Protein kinase A inhibitor | 0.074 0.066 DBMET02709 | DBMET02709 | |
| 0.029 | 0.172 | 0.302 | Carbonic anhydrase XIII inhibitor | 0.217 0.012 DBMET02709 0.302 0.006 DBMET02710 | DBMET02710 | |
| 0.026 | 0.169 | 0.198 | Catalase inhibitor | 0.148 0.027 DBMET02709 0.141 0.028 DBMET02710 0.198 0.015 DBMET02711 | DBMET02711 | |
| 0.055 | 0.199 | 0.218 | MAP kinase kinase inhibitor | 0.202 0.028 DBMET02709 0.218 0.023 DBMET02710 | DBMET02710 | |
| 0.083 | 0.227 | 0.153 | Sphingosine 1-phosphate receptor 2 antagonist | 0.153 0.037 DBMET02709 0.153 0.037 DBMET02710 | DBMET02710 | |
| 0.018 | 0.163 | 0.235 | NMDA 2 receptor antagonist | 0.063 0.058 DBMET02707 0.149 0.017 DBMET02709 0.235 0.007 DBMET02710 | DBMET02710 | |
| 0.08 | 0.224 | 0.154 | Thiol protease inhibitor | 0.154 0.065 DBMET02709 0.127 0.103 DBMET02710 | DBMET02709 | |
| 0.045 | 0.19 | 0.178 | Prolactin inhibitor | 0.145 0.024 DBMET02709 0.178 0.013 DBMET02710 | DBMET02710 | |
| 0.008 | 0.153 | 0.072 | Carbonic anhydrase IV inhibitor | 0.072 0.014 DBMET02709 0.065 0.017 DBMET02710 | DBMET02709 | |
| 0.019 | 0.166 | 0.086 | HIV-1 integrase (Strand Transfer) inhibitor | 0.086 0.028 DBMET02710 0.053 0.047 DBMET02711 | DBMET02710 | |
| 0.135 | 0.282 | 0.367 | Alpha-glucosidase inhibitor | 0.243 0.192 DBMET02709 0.367 0.128 DBMET02710 | DBMET02710 | |
| 0.009 | 0.156 | 0.046 | Urate transporter 1 inhibitor | 0.04 0.026 DBMET02709 0.046 0.021 DBMET02710 | DBMET02710 | |
| 0.016 | 0.163 | 0.032 | Melatonin receptor 1A agonist | 0.032 0.027 DBMET02709 | DBMET02709 | |
| 0.028 | 0.176 | 0.048 | Dipeptidyl peptidase inhibitor | 0.048 0.046 DBMET02709 | DBMET02709 | |
| 0.064 | 0.212 | 0.102 | CDC-like kinase 3 inhibitor | 0.102 0.076 DBMET02709 | DBMET02709 | |
| 0.006 | 0.156 | 0.049 | Acetylcholine M4 receptor agonist | 0.049 0.012 DBMET02709 | DBMET02709 | |
| 0.011 | 0.162 | 0.04 | Lysophosphatidic acid 2 receptor antagonist | 0.04 0.012 DBMET02709 0.033 0.018 DBMET02710 | DBMET02709 | |
| 0.005 | 0.155 | 0.068 | Dopamine autoreceptor agonist | 0.055 0.006 DBMET02709 0.068 0.005 DBMET02710 | DBMET02710 | |
| 0.017 | 0.168 | 0.157 | NMDA receptor subunit 3B antagonist | 0.081 0.013 DBMET02709 0.157 0.005 DBMET02710 | DBMET02710 | |
| 0.05 | 0.203 | 0.192 | Phosphodiesterase 7B inhibitor | 0.192 0.011 DBMET02709 | DBMET02709 | |
| 0.02 | 0.172 | 0.086 | 5 Hydroxytryptamine 6 antagonist | 0.086 0.02 DBMET02709 | DBMET02709 | |
| 0.007 | 0.16 | 0.045 | Factor VII inhibitor | 0.045 0.013 DBMET02709 | DBMET02709 | |
| 0.024 | 0.177 | 0.086 | Benzodiazepine agonist | 0.086 0.034 DBMET02709 | DBMET02709 | |
| 0.033 | 0.186 | 0.077 | Protease 3C (Human rhinovirus) inhibitor | 0.077 0.03 DBMET02709 0.061 0.051 DBMET02710 | DBMET02709 | |
| 0.061 | 0.214 | 0.217 | Cyclooxygenase 3 inhibitor | 0.199 0.019 DBMET02709 0.217 0.014 DBMET02710 | DBMET02710 | |
| 0.033 | 0.188 | 0.077 | 5 Hydroxytryptamine 5A antagonist | 0.077 0.025 DBMET02709 0.062 0.041 DBMET02710 | DBMET02709 | |
| 0.013 | 0.169 | 0.041 | Histone deacetylase 7 inhibitor | 0.041 0.022 DBMET02709 | DBMET02709 | |
| 0.013 | 0.168 | 0.039 | Angiotensin AT1 receptor antagonist | 0.039 0.036 DBMET02709 | DBMET02709 | |
| 0.029 | 0.185 | 0.11 | CD45 antagonist | 0.08 0.012 DBMET02709 0.11 0.008 DBMET02710 | DBMET02710 | |
| 0.008 | 0.164 | 0.056 | Kainate receptor 2 antagonist | 0.056 0.013 DBMET02709 0.035 0.026 DBMET02710 | DBMET02709 | |
| 0.05 | 0.207 | 0.103 | Polo-like kinase-1 inhibitor | 0.103 0.042 DBMET02709 0.083 0.076 DBMET02710 | DBMET02709 | |
| 0.047 | 0.204 | 0.107 | Phosphodiesterase I inhibitor | 0.107 0.037 DBMET02709 0.098 0.046 DBMET02710 | DBMET02709 | |
| 0.027 | 0.185 | 0.047 | Bombesin 2 receptor antagonist | 0.047 0.038 DBMET02709 0.045 0.042 DBMET02710 | DBMET02709 | |
| 0.036 | 0.195 | 0.112 | Glycine receptor antagonist | 0.112 0.023 DBMET02709 0.09 0.043 DBMET02710 | DBMET02709 | |
| 0.032 | 0.191 | 0.104 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.08 0.019 DBMET02709 0.104 0.009 DBMET02710 | DBMET02710 | |
| 0.025 | 0.184 | 0.081 | Glutamate receptor agonist | 0.081 0.052 DBMET02709 | DBMET02709 | |
| 0.023 | 0.182 | 0.072 | 5 Hydroxytryptamine 3A antagonist | 0.072 0.039 DBMET02709 | DBMET02709 | |
| 0.039 | 0.199 | 0.153 | Urease inhibitor | 0.132 0.035 DBMET02709 0.147 0.024 DBMET02710 0.153 0.022 DBMET02711 | DBMET02711 | |
| 0.029 | 0.189 | 0.068 | 5 Hydroxytryptamine 5 antagonist | 0.068 0.027 DBMET02709 0.054 0.046 DBMET02710 | DBMET02709 | |
| 0.029 | 0.189 | 0.092 | Beta adrenoreceptor antagonist | 0.066 0.044 DBMET02709 0.092 0.02 DBMET02710 | DBMET02710 | |
| 0.066 | 0.228 | 0.173 | Acetylcholine M1 receptor antagonist | 0.173 0.057 DBMET02709 0.169 0.059 DBMET02710 | DBMET02709 | |
| 0.037 | 0.2 | 0.079 | Phosphodiesterase 1C inhibitor | 0.079 0.02 DBMET02709 0.071 0.028 DBMET02710 | DBMET02709 | |
| 0.031 | 0.196 | 0.092 | MAP-kinase-activated kinase 2 inhibitor | 0.092 0.034 DBMET02709 | DBMET02709 | |
| 0.066 | 0.231 | 0.214 | Interleukin 8 antagonist | 0.2 0.013 DBMET02709 0.214 0.01 DBMET02710 | DBMET02710 | |
| 0.019 | 0.185 | 0.053 | Benzodiazepine antagonist | 0.053 0.022 DBMET02709 | DBMET02709 | |
| 0.05 | 0.217 | 0.378 | Amylase inhibitor | 0.266 0.024 DBMET02709 0.378 0.011 DBMET02710 0.261 0.025 DBMET02711 | DBMET02710 | |
| 0.045 | 0.212 | 0.089 | Vanilloid 4 agonist | 0.089 0.027 DBMET02709 | DBMET02709 | |
| 0.004 | 0.171 | 0.042 | AMPA 1 receptor antagonist | 0.042 0.014 DBMET02709 0.042 0.014 DBMET02710 | DBMET02710 | |
| 0.025 | 0.193 | 0.057 | Beta adrenoreceptor agonist | 0.045 0.032 DBMET02709 0.057 0.01 DBMET02710 | DBMET02710 | |
| 0.004 | 0.172 | 0.026 | 5 Hydroxytryptamine 1D agonist | 0.026 0.023 DBMET02709 | DBMET02709 | |
| 0.031 | 0.201 | 0.062 | Pregnane X receptor antagonist | 0.062 0.026 DBMET02709 0.061 0.028 DBMET02710 | DBMET02709 | |
| 0.034 | 0.206 | 0.083 | Potassium channel (Tandem pore domain) blocker | 0.083 0.028 DBMET02709 | DBMET02709 | |
| 0.012 | 0.184 | 0.052 | Acetylcholine muscarinic agonist | 0.052 0.04 DBMET02709 | DBMET02709 | |
| 0.029 | 0.202 | 0.053 | Alpha 1b adrenoreceptor agonist | 0.053 0.029 DBMET02709 | DBMET02709 | |
| 0.011 | 0.183 | 0.038 | ATP citrate lysase inhibitor | 0.038 0.015 DBMET02710 | DBMET02710 | |
| 0.039 | 0.212 | 0.12 | c-Src kinase inhibitor | 0.12 0.075 DBMET02709 0.108 0.084 DBMET02710 | DBMET02709 | |
| 0.019 | 0.193 | 0.079 | Beta 1 adrenoreceptor antagonist | 0.06 0.035 DBMET02709 0.079 0.019 DBMET02710 | DBMET02710 | |
| 0.008 | 0.182 | 0.035 | 5 Hydroxytryptamine 3B antagonist | 0.035 0.026 DBMET02709 | DBMET02709 | |
| 0.037 | 0.211 | 0.103 | MAP-kinase-activated kinase inhibitor | 0.103 0.037 DBMET02709 | DBMET02709 | |
| 0.072 | 0.247 | 0.501 | Anesthetic general | 0.479 0.009 DBMET02709 0.501 0.008 DBMET02710 | DBMET02710 | |
| 0.022 | 0.197 | 0.07 | Sphingosine 1-phosphate receptor 3 antagonist | 0.07 0.026 DBMET02709 0.069 0.027 DBMET02710 | DBMET02709 | |
| 0.029 | 0.204 | 0.173 | MAO A inhibitor | 0.116 0.054 DBMET02709 0.173 0.035 DBMET02710 | DBMET02710 | |
| 0.031 | 0.206 | 0.061 | Phosphodiesterase 1A inhibitor | 0.061 0.038 DBMET02709 | DBMET02709 | |
| 0.029 | 0.206 | 0.104 | Calcium antagonist | 0.104 0.045 DBMET02709 | DBMET02709 | |
| 0.037 | 0.214 | 0.115 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.115 0.073 DBMET02709 | DBMET02709 | |
| 0.037 | 0.214 | 0.114 | Abl kinase inhibitor | 0.114 0.073 DBMET02709 | DBMET02709 | |
| 0.017 | 0.194 | 0.054 | Alpha 1 adrenoreceptor agonist | 0.054 0.045 DBMET02709 | DBMET02709 | |
| 0.022 | 0.199 | 0.057 | Leukotriene B4 antagonist | 0.057 0.032 DBMET02710 | DBMET02710 | |
| 0.014 | 0.192 | 0.033 | Complement factor 1r inhibitor | 0.033 0.008 DBMET02709 | DBMET02709 | |
| 0.034 | 0.212 | 0.133 | Check point kinase 2 inhibitor | 0.133 0.04 DBMET02709 0.093 0.072 DBMET02710 | DBMET02709 | |
| 0.022 | 0.201 | 0.052 | Aldosterone antagonist | 0.052 0.027 DBMET02709 | DBMET02709 | |
| 0.043 | 0.222 | 0.147 | Alpha 2b adrenoreceptor antagonist | 0.147 0.04 DBMET02709 0.121 0.058 DBMET02710 | DBMET02709 | |
| 0.005 | 0.184 | 0.051 | Methionyl aminopeptidase 2 inhibitor | 0.051 0.006 DBMET02709 0.031 0.013 DBMET02710 | DBMET02709 | |
| 0.022 | 0.202 | 0.089 | Lysine-specific demethylase 1A inhibitor | 0.089 0.009 DBMET02709 0.08 0.012 DBMET02710 | DBMET02709 | |
| 0.044 | 0.224 | 0.119 | Alpha 2c adrenoreceptor antagonist | 0.119 0.05 DBMET02709 0.098 0.068 DBMET02710 | DBMET02709 | |
| 0.003 | 0.183 | 0.013 | Human herpes virus 5 capsid protein P40 inhibitor | 0.013 0.009 DBMET02709 | DBMET02709 | |
| 0.026 | 0.207 | 0.087 | Acetylcholine nicotinic antagonist | 0.087 0.048 DBMET02709 | DBMET02709 | |
| 0.069 | 0.25 | 0.144 | Sphingosine 1-phosphate receptor 4 antagonist | 0.144 0.039 DBMET02709 0.129 0.057 DBMET02710 | DBMET02709 | |
| 0.032 | 0.213 | 0.068 | Protein kinase B gamma inhibitor | 0.068 0.06 DBMET02709 | DBMET02709 | |
| 0.02 | 0.202 | 0.12 | MAO B inhibitor | 0.083 0.073 DBMET02709 0.12 0.051 DBMET02710 | DBMET02710 | |
| 0.064 | 0.247 | 0.249 | Protein kinase stimulant | 0.188 0.046 DBMET02709 0.249 0.027 DBMET02710 | DBMET02710 | |
| 0.022 | 0.205 | 0.102 | Alpha adrenoreceptor agonist | 0.102 0.027 DBMET02709 0.09 0.032 DBMET02710 | DBMET02709 | |
| 0.03 | 0.215 | 0.1 | Acetylcholine nicotinic agonist | 0.1 0.037 DBMET02709 | DBMET02709 | |
| 0.009 | 0.195 | 0.103 | AMPA receptor antagonist | 0.103 0.011 DBMET02709 0.092 0.014 DBMET02710 | DBMET02709 | |
| 0.017 | 0.208 | 0.06 | Nicotinic receptor alpha7 subunit antagonist | 0.06 0.029 DBMET02709 | DBMET02709 | |
| 0.014 | 0.205 | 0.127 | Carbonic anhydrase XIV inhibitor | 0.096 0.012 DBMET02709 0.127 0.006 DBMET02710 | DBMET02710 | |
| 0.093 | 0.285 | 0.196 | MAP kinase kinase 4 inhibitor | 0.158 0.048 DBMET02709 0.196 0.015 DBMET02710 | DBMET02710 | |
| 0.108 | 0.302 | 0.291 | Gastrin inhibitor | 0.291 0.039 DBMET02709 0.241 0.09 DBMET02710 | DBMET02709 | |
| 0.058 | 0.253 | 0.199 | Toll-Like receptor antagonist | 0.199 0.031 DBMET02709 0.184 0.037 DBMET02710 | DBMET02709 | |
| 0.027 | 0.222 | 0.214 | NMDA receptor antagonist | 0.133 0.03 DBMET02709 0.214 0.012 DBMET02710 | DBMET02710 | |
| 0.02 | 0.216 | 0.037 | Vanilloid 3 antagonist | 0.037 0.029 DBMET02709 | DBMET02709 | |
| 0.016 | 0.212 | 0.064 | Potassium channel (Inward rectifier) blocker | 0.064 0.021 DBMET02709 | DBMET02709 | |
| 0.032 | 0.229 | 0.176 | MAO inhibitor | 0.123 0.073 DBMET02709 0.176 0.049 DBMET02710 | DBMET02710 | |
| 0.047 | 0.244 | 0.104 | Caspase 3 inhibitor | 0.102 0.089 DBMET02709 0.104 0.086 DBMET02710 | DBMET02710 | |
| 0.083 | 0.282 | 0.134 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.128 0.12 DBMET02709 0.134 0.107 DBMET02710 | DBMET02710 | |
| 0.041 | 0.24 | 0.105 | Glutathione S-transferase inhibitor | 0.087 0.051 DBMET02709 0.092 0.045 DBMET02710 0.105 0.033 DBMET02711 | DBMET02711 | |
| 0.047 | 0.246 | 0.209 | Alkaline phosphatase inhibitor | 0.163 0.052 DBMET02709 0.209 0.03 DBMET02710 0.171 0.047 DBMET02711 | DBMET02710 | |
| 0.055 | 0.254 | 0.198 | Toll-Like receptor 2 antagonist | 0.147 0.055 DBMET02709 0.198 0.024 DBMET02710 | DBMET02710 | |
| 0.024 | 0.224 | 0.06 | MAP kinase kinase 9 inhibitor | 0.06 0.031 DBMET02709 | DBMET02709 | |
| 0.021 | 0.221 | 0.082 | Protein kinase C beta inhibitor | 0.081 0.028 DBMET02709 0.082 0.028 DBMET02710 | DBMET02710 | |
| 0.008 | 0.212 | 0.284 | Histone deacetylase 2 inhibitor | 0.284 0.005 DBMET02708 0.057 0.013 DBMET02709 0.03 0.028 DBMET02710 | DBMET02708 | |
| 0.014 | 0.218 | 0.072 | 5 Hydroxytryptamine 4 antagonist | 0.072 0.016 DBMET02709 0.052 0.034 DBMET02710 | DBMET02709 | |
| 0.113 | 0.318 | 0.309 | Vasodilator, peripheral | 0.299 0.097 DBMET02709 0.309 0.092 DBMET02710 | DBMET02710 | |
| 0.019 | 0.224 | 0.077 | Neuronal nicotinic receptor antagonist | 0.077 0.039 DBMET02709 | DBMET02709 | |
| 0.009 | 0.216 | 0.031 | Thyroid hormone agonist | 0.031 0.012 DBMET02710 | DBMET02710 | |
| 0.031 | 0.238 | 0.113 | Beta 3 adrenoreceptor antagonist | 0.077 0.026 DBMET02709 0.113 0.011 DBMET02710 | DBMET02710 | |
| 0.03 | 0.238 | 0.154 | Adrenaline agonist | 0.096 0.04 DBMET02709 0.154 0.014 DBMET02710 | DBMET02710 | |
| 0.044 | 0.251 | 0.133 | Nav1.3 sodium channel blocker | 0.133 0.061 DBMET02709 | DBMET02709 | |
| 0.006 | 0.214 | 0.025 | Sodium/glucose cotransporter 2 inhibitor | 0.025 0.02 DBMET02710 | DBMET02710 | |
| 0.043 | 0.251 | 0.084 | MDM2 inhibitor | 0.084 0.016 DBMET02709 0.07 0.037 DBMET02710 | DBMET02709 | |
| 0.08 | 0.288 | 0.147 | Pregnane X receptor agonist | 0.147 0.058 DBMET02709 0.139 0.076 DBMET02710 | DBMET02709 | |
| 0.024 | 0.232 | 0.054 | 5 Hydroxytryptamine 7 agonist | 0.054 0.042 DBMET02709 | DBMET02709 | |
| 0.075 | 0.285 | 0.148 | Vanilloid 1 agonist | 0.131 0.064 DBMET02709 0.148 0.04 DBMET02710 | DBMET02710 | |
| 0.043 | 0.253 | 0.135 | Beta glucuronidase inhibitor | 0.098 0.073 DBMET02709 0.135 0.034 DBMET02710 | DBMET02710 | |
| 0.035 | 0.248 | 0.108 | Gastric antisecretory | 0.108 0.056 DBMET02709 0.089 0.08 DBMET02710 | DBMET02709 | |
| 0.008 | 0.222 | 0.025 | Calcium-sensing receptor agonist | 0.025 0.022 DBMET02709 | DBMET02709 | |
| 0.045 | 0.259 | 0.239 | Toll-Like receptor 9 antagonist | 0.239 0.023 DBMET02709 0.191 0.039 DBMET02710 | DBMET02709 | |
| 0.15 | 0.369 | 0.2 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.2 0.166 DBMET02709 | DBMET02709 | |
| 0.041 | 0.261 | 0.114 | Epidermal growth factor receptor kinase inhibitor | 0.114 0.08 DBMET02709 | DBMET02709 | |
| 0.073 | 0.293 | 0.203 | Melanin inhibitor | 0.145 0.088 DBMET02709 0.203 0.04 DBMET02710 | DBMET02710 | |
| 0.05 | 0.274 | 0.138 | Cytokine production inhibitor | 0.138 0.072 DBMET02709 0.106 0.104 DBMET02710 | DBMET02709 | |
| 0.062 | 0.288 | 0.268 | Anticonvulsant | 0.268 0.05 DBMET02709 0.149 0.13 DBMET02710 | DBMET02709 | |
| 0.01 | 0.237 | 0.129 | Aromatase inhibitor | 0.092 0.023 DBMET02709 0.129 0.016 DBMET02710 | DBMET02710 | |
| 0.012 | 0.241 | 0.036 | Factor XIIIa inhibitor | 0.036 0.028 DBMET02709 | DBMET02709 | |
| 0.007 | 0.239 | 0.024 | Sodium/glucose cotransporter inhibitor | 0.024 0.023 DBMET02710 | DBMET02710 | |
| 0.042 | 0.275 | 0.16 | DNA polymerase I inhibitor | 0.16 0.044 DBMET02710 | DBMET02710 | |
| 0.005 | 0.238 | 0.03 | HCV NS5B polymerase inhibitor | 0.03 0.024 DBMET02710 | DBMET02710 | |
| 0.024 | 0.258 | 0.054 | Nicotinic alpha3beta2 receptor antagonist | 0.054 0.035 DBMET02709 | DBMET02709 | |
| 0.023 | 0.258 | 0.075 | Alpha 2a adrenoreceptor antagonist | 0.075 0.052 DBMET02709 0.067 0.062 DBMET02710 | DBMET02709 | |
| 0.067 | 0.303 | 0.227 | Polo-like kinase-3 inhibitor | 0.227 0.033 DBMET02709 0.138 0.098 DBMET02710 | DBMET02709 | |
| 0.009 | 0.247 | 0.091 | Factor VIIa inhibitor | 0.074 0.014 DBMET02708 0.091 0.012 DBMET02709 0.037 0.027 DBMET02710 | DBMET02709 | |
| 0.092 | 0.331 | 0.24 | Histone acetyltransferase inhibitor | 0.24 0.03 DBMET02709 0.232 0.035 DBMET02710 | DBMET02709 | |
| 0.01 | 0.252 | 0.048 | Leukocyte elastase inhibitor | 0.048 0.025 DBMET02709 | DBMET02709 | |
| 0.039 | 0.281 | 0.126 | Bile acid receptor antagonist | 0.112 0.028 DBMET02709 0.126 0.015 DBMET02710 | DBMET02710 | |
| 0.049 | 0.291 | 0.302 | NADPH oxidase inhibitor | 0.237 0.024 DBMET02709 0.302 0.012 DBMET02710 | DBMET02710 | |
| 0.007 | 0.251 | 0.029 | Liver X receptor beta antagonist | 0.029 0.02 DBMET02710 | DBMET02710 | |
| 0.013 | 0.258 | 0.078 | Acetylcholine M5 receptor agonist | 0.078 0.036 DBMET02709 | DBMET02709 | |
| 0.029 | 0.275 | 0.148 | Vascular endothelial growth factor 1 antagonist | 0.148 0.042 DBMET02709 | DBMET02709 | |
| 0.024 | 0.271 | 0.089 | Acetylcholine agonist | 0.089 0.056 DBMET02709 | DBMET02709 | |
| 0.032 | 0.279 | 0.125 | Cholesterol synthesis inhibitor | 0.097 0.092 DBMET02709 0.125 0.061 DBMET02710 | DBMET02710 | |
| 0.092 | 0.342 | 0.229 | Transcription factor STAT3 inhibitor | 0.205 0.127 DBMET02709 0.229 0.102 DBMET02710 | DBMET02710 | |
| 0.023 | 0.273 | 0.084 | Fibroblast growth factor 1 antagonist | 0.084 0.071 DBMET02709 | DBMET02709 | |
| 0.013 | 0.264 | 0.062 | 5 Hydroxytryptamine 3 antagonist | 0.062 0.034 DBMET02709 | DBMET02709 | |
| 0.007 | 0.26 | 0.068 | Glutamate (mGluR1) antagonist | 0.068 0.032 DBMET02709 | DBMET02709 | |
| 0.033 | 0.286 | 0.116 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.095 0.044 DBMET02709 0.116 0.027 DBMET02710 | DBMET02710 | |
| 0.023 | 0.276 | 0.078 | Cathepsin G inhibitor | 0.078 0.045 DBMET02709 0.075 0.048 DBMET02710 | DBMET02709 | |
| 0.017 | 0.271 | 0.095 | Androgen agonist | 0.075 0.027 DBMET02709 0.095 0.017 DBMET02710 | DBMET02710 | |
| 0.012 | 0.267 | 0.082 | Neuraminidase inhibitor | 0.082 0.024 DBMET02710 | DBMET02710 | |
| 0.009 | 0.264 | 0.023 | ICAM 1 antagonist | 0.023 0.015 DBMET02709 0.022 0.019 DBMET02710 | DBMET02709 | |
| 0.047 | 0.304 | 0.113 | Phosphodiesterase 6D inhibitor | 0.108 0.039 DBMET02709 0.113 0.032 DBMET02710 | DBMET02710 | |
| 0.01 | 0.269 | 0.032 | RNA-directed RNA polymerase inhibitor | 0.032 0.027 DBMET02710 | DBMET02710 | |
| 0.036 | 0.295 | 0.131 | GABA receptor agonist | 0.131 0.048 DBMET02709 0.1 0.076 DBMET02710 | DBMET02709 | |
| 0.014 | 0.274 | 0.052 | Dopamine uptake inhibitor | 0.052 0.046 DBMET02709 | DBMET02709 | |
| 0.008 | 0.271 | 0.039 | Histone deacetylase 8 inhibitor | 0.039 0.031 DBMET02709 | DBMET02709 | |
| 0.09 | 0.354 | 0.241 | Transcription factor STAT inhibitor | 0.212 0.122 DBMET02709 0.241 0.093 DBMET02710 | DBMET02710 | |
| 0.024 | 0.288 | 0.063 | Phosphodiesterase 1B inhibitor | 0.063 0.038 DBMET02709 0.054 0.052 DBMET02710 | DBMET02709 | |
| 0.077 | 0.341 | 0.193 | Thioredoxin glutathione reductase inhibitor | 0.193 0.178 DBMET02707 | DBMET02707 | |
| 0.014 | 0.28 | 0.048 | Nicotinic alpha7 receptor agonist | 0.048 0.046 DBMET02709 | DBMET02709 | |
| 0.052 | 0.321 | 0.138 | CDK3/cyclin E inhibitor | 0.138 0.036 DBMET02709 0.11 0.07 DBMET02710 | DBMET02709 | |
| 0.005 | 0.277 | 0.084 | Histone deacetylase 1 inhibitor | 0.084 0.009 DBMET02708 0.083 0.009 DBMET02709 | DBMET02708 | |
| 0.03 | 0.302 | 0.082 | GABA A receptor agonist | 0.082 0.06 DBMET02709 | DBMET02709 | |
| 0.033 | 0.308 | 0.104 | Acetylcholine muscarinic antagonist | 0.104 0.086 DBMET02709 0.102 0.089 DBMET02710 | DBMET02709 | |
| 0.013 | 0.288 | 0.044 | Plasmepsin II inhibitor | 0.044 0.024 DBMET02709 0.038 0.034 DBMET02710 | DBMET02709 | |
| 0.022 | 0.299 | 0.082 | Alpha 2 adrenoreceptor antagonist | 0.082 0.064 DBMET02709 | DBMET02709 | |
| 0.092 | 0.371 | 0.123 | CC chemokine 6 receptor antagonist | 0.123 0.102 DBMET02710 | DBMET02710 | |
| 0.013 | 0.292 | 0.057 | Leukotriene antagonist | 0.057 0.056 DBMET02710 | DBMET02710 | |
| 0.027 | 0.307 | 0.125 | Polo-like kinase-4 inhibitor | 0.125 0.052 DBMET02709 | DBMET02709 | |
| 0.005 | 0.286 | 0.101 | Estradiol 17 beta-dehydrogenase inhibitor | 0.037 0.034 DBMET02709 0.101 0.01 DBMET02710 | DBMET02710 | |
| 0.092 | 0.374 | 0.266 | Neuropeptide Y2 antagonist | 0.266 0.042 DBMET02709 0.263 0.045 DBMET02710 | DBMET02709 | |
| 0.004 | 0.293 | 0.043 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.043 0.014 DBMET02710 | DBMET02710 | |
| 0.004 | 0.301 | 0.042 | Histone deacetylase 3 inhibitor | 0.042 0.011 DBMET02709 | DBMET02709 | |
| 0.042 | 0.34 | 0.125 | Calcium channel N-type blocker | 0.125 0.058 DBMET02709 | DBMET02709 | |
| 0.097 | 0.397 | 0.37 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.238 0.118 DBMET02708 0.37 0.029 DBMET02709 0.302 0.062 DBMET02710 | DBMET02709 | |
| 0.01 | 0.313 | 0.057 | Acetylcholine M5 receptor antagonist | 0.057 0.047 DBMET02709 | DBMET02709 | |
| 0.033 | 0.339 | 0.315 | Psychostimulant | 0.315 0.039 DBMET02709 0.294 0.044 DBMET02710 | DBMET02709 | |
| 0.056 | 0.363 | 0.328 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.328 0.029 DBMET02709 0.201 0.075 DBMET02710 | DBMET02709 | |
| 0.034 | 0.347 | 0.106 | Proteasome inhibitor | 0.106 0.079 DBMET02709 0.101 0.086 DBMET02710 | DBMET02709 | |
| 0.041 | 0.355 | 0.154 | Phospholipase A2 inhibitor | 0.133 0.096 DBMET02709 0.154 0.07 DBMET02710 | DBMET02710 | |
| 0.006 | 0.321 | 0.031 | LFA antagonist | 0.031 0.014 DBMET02709 | DBMET02709 | |
| 0.011 | 0.326 | 0.052 | Prolyl endopeptidase inhibitor | 0.052 0.034 DBMET02709 | DBMET02709 | |
| 0.032 | 0.348 | 0.1 | Estrogen receptor alpha antagonist | 0.1 0.027 DBMET02710 | DBMET02710 | |
| 0.058 | 0.376 | 0.234 | Non-steroidal antiinflammatory agent | 0.221 0.057 DBMET02709 0.234 0.05 DBMET02710 | DBMET02710 | |
| 0.015 | 0.335 | 0.098 | Platelet activating factor beta antagonist | 0.098 0.064 DBMET02709 | DBMET02709 | |
| 0.015 | 0.337 | 0.036 | Glutamate (mGluR8) antagonist | 0.036 0.024 DBMET02709 0.033 0.031 DBMET02710 | DBMET02709 | |
| 0.044 | 0.376 | 0.082 | Hematopoietic | 0.082 0.067 DBMET02709 0.081 0.07 DBMET02710 | DBMET02709 | |
| 0.039 | 0.382 | 0.081 | Transcription factor NF kappa B stimulant | 0.081 0.067 DBMET02710 | DBMET02710 | |
| 0.015 | 0.365 | 0.075 | Dopamine D1 antagonist | 0.075 0.036 DBMET02710 | DBMET02710 | |
| 0.034 | 0.388 | 0.154 | Antibacterial (Helicobacter pylori) | 0.111 0.097 DBMET02709 0.107 0.104 DBMET02710 0.154 0.043 DBMET02711 | DBMET02711 | |
| 0.027 | 0.382 | 0.366 | Chelator | 0.197 0.025 DBMET02710 0.366 0.007 DBMET02711 | DBMET02711 | |
| 0.021 | 0.377 | 0.123 | Mediator release inhibitor | 0.103 0.066 DBMET02709 0.123 0.045 DBMET02710 | DBMET02710 | |
| 0.001 | 0.357 | 0.006 | Insulin like growth factor 3 antagonist | 0.006 0.004 DBMET02710 | DBMET02710 | |
| 0.008 | 0.368 | 0.034 | Growth factor receptor-bound protein 2 antagonist | 0.034 0.027 DBMET02709 0.033 0.028 DBMET02710 | DBMET02709 | |
| 0.068 | 0.43 | 0.471 | Lipocortins synthesis antagonist | 0.471 0.005 DBMET02709 0.397 0.009 DBMET02710 | DBMET02709 | |
| 0.024 | 0.392 | 0.088 | I kappa B kinase 1 inhibitor | 0.088 0.03 DBMET02709 | DBMET02709 | |
| 0.044 | 0.418 | 0.09 | Transforming growth factor beta 3 antagonist | 0.09 0.038 DBMET02709 | DBMET02709 | |
| 0.009 | 0.384 | 0.052 | CC chemokine 2 receptor antagonist | 0.052 0.042 DBMET02709 | DBMET02709 | |
| 0.009 | 0.396 | 0.069 | Aminopeptidase N inhibitor | 0.069 0.021 DBMET02711 | DBMET02711 | |
| 0.021 | 0.411 | 0.101 | 5 Hydroxytryptamine 2B antagonist | 0.101 0.082 DBMET02709 | DBMET02709 | |
| 0.013 | 0.408 | 0.068 | Protein kinase C alpha inhibitor | 0.068 0.046 DBMET02709 | DBMET02709 | |
| 0.012 | 0.412 | 0.116 | Androgen antagonist | 0.089 0.056 DBMET02709 0.116 0.035 DBMET02710 | DBMET02710 | |
| 0.019 | 0.423 | 0.13 | Vascular endothelial growth factor 3 antagonist | 0.13 0.085 DBMET02709 | DBMET02709 | |
| 0.034 | 0.439 | 0.233 | Spasmolytic | 0.206 0.115 DBMET02709 0.233 0.099 DBMET02710 | DBMET02710 | |
| 0.117 | 0.523 | 0.556 | Calcium channel L-type activator | 0.248 0.207 DBMET02708 0.531 0.018 DBMET02709 0.556 0.012 DBMET02710 | DBMET02710 | |
| 0.024 | 0.435 | 0.085 | Factor XII inhibitor | 0.085 0.057 DBMET02711 | DBMET02711 | |
| 0.058 | 0.47 | 0.19 | Sphingosine 1-phosphate receptor 2 agonist | 0.147 0.027 DBMET02707 0.19 0.013 DBMET02708 | DBMET02708 | |
| 0.022 | 0.439 | 0.186 | Telomerase inhibitor | 0.186 0.015 DBMET02709 0.102 0.032 DBMET02710 | DBMET02709 | |
| 0.039 | 0.461 | 0.249 | Interleukin 4 antagonist | 0.249 0.013 DBMET02710 | DBMET02710 | |
| 0.013 | 0.439 | 0.089 | Aminopeptidase microsomal inhibitor | 0.089 0.021 DBMET02711 | DBMET02711 | |
| 0.008 | 0.441 | 0.121 | Endothelin-converting enzyme inhibitor | 0.121 0.012 DBMET02711 | DBMET02711 | |
| 0.09 | 0.524 | 0.499 | ErbB-1 antagonist | 0.499 0.008 DBMET02709 0.413 0.014 DBMET02710 | DBMET02709 | |
| 0.021 | 0.458 | 0.125 | AMP-activated protein kinase stimulant | 0.094 0.079 DBMET02709 0.125 0.044 DBMET02710 | DBMET02710 | |
| 0.008 | 0.447 | 0.07 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.07 0.06 DBMET02710 | DBMET02710 | |
| 0.1 | 0.545 | 0.427 | MAP kinase kinase 6 inhibitor | 0.427 0.044 DBMET02709 0.266 0.171 DBMET02710 | DBMET02709 | |
| 0.008 | 0.476 | 0.061 | Check point kinase 1 inhibitor | 0.061 0.058 DBMET02710 | DBMET02710 | |
| 0.017 | 0.487 | 0.199 | Cyclooxygenase 1 inhibitor | 0.133 0.068 DBMET02709 0.199 0.035 DBMET02710 | DBMET02710 | |
| 0.005 | 0.488 | 0.014 | Integrin beta6 antagonist | 0.014 0.01 DBMET02710 | DBMET02710 | |
| 0.035 | 0.519 | 0.102 | T cell inhibitor | 0.102 0.023 DBMET02709 0.08 0.064 DBMET02710 | DBMET02709 | |
| 0.058 | 0.542 | 0.17 | Death-associated protein kinase 2 inhibitor | 0.141 0.128 DBMET02709 0.17 0.067 DBMET02710 | DBMET02710 | |
| 0.01 | 0.496 | 0.041 | Purinergic P2Y2 antagonist | 0.041 0.015 DBMET02709 0.034 0.023 DBMET02710 | DBMET02709 | |
| 0.03 | 0.536 | 0.396 | Antioxidant | 0.396 0.036 DBMET02710 0.358 0.044 DBMET02711 | DBMET02710 | |
| 0.019 | 0.527 | 0.162 | Potassium channel large-conductance Ca-activated activator | 0.084 0.032 DBMET02709 0.162 0.009 DBMET02710 | DBMET02710 | |
| 0.019 | 0.528 | 0.122 | Breast cancer-resistant protein inhibitor | 0.086 0.071 DBMET02709 0.122 0.038 DBMET02710 | DBMET02710 | |
| 0.011 | 0.526 | 0.155 | Glutamate receptor antagonist | 0.155 0.048 DBMET02709 0.145 0.054 DBMET02710 | DBMET02709 | |
| 0.005 | 0.52 | 0.156 | NMDA 2B receptor antagonist | 0.055 0.035 DBMET02707 0.101 0.015 DBMET02708 0.07 0.025 DBMET02709 0.156 0.009 DBMET02710 | DBMET02710 | |
| 0.021 | 0.558 | 0.173 | Dual specificity phosphatase inhibitor | 0.141 0.105 DBMET02707 0.173 0.073 DBMET02710 0.157 0.087 DBMET02711 | DBMET02710 | |
| 0.076 | 0.62 | 0.5 | Interleukin 2 agonist | 0.218 0.16 DBMET02707 0.268 0.1 DBMET02708 0.5 0.008 DBMET02709 0.477 0.011 DBMET02710 0.247 0.122 DBMET02711 | DBMET02709 | |
| 0.017 | 0.564 | 0.12 | Cyclooxygenase inhibitor | 0.12 0.099 DBMET02710 | DBMET02710 | |
| 0.01 | 0.562 | 0.08 | Platelet growth factor antagonist | 0.08 0.057 DBMET02709 | DBMET02709 | |
| 0.029 | 0.583 | 0.141 | Antipruritic | 0.141 0.106 DBMET02709 0.136 0.113 DBMET02710 | DBMET02709 | |
| 0.013 | 0.567 | 0.109 | DNA intercalator | 0.106 0.067 DBMET02709 0.109 0.065 DBMET02710 | DBMET02710 | |
| 0.016 | 0.571 | 0.064 | Factor III inhibitor | 0.049 0.037 DBMET02709 0.064 0.015 DBMET02710 | DBMET02710 | |
| 0.005 | 0.563 | 0.022 | Protein 30S ribosomal subunit inhibitor | 0.022 0.02 DBMET02710 | DBMET02710 | |
| 0.053 | 0.644 | 0.588 | Apoptosis antagonist | 0.225 0.152 DBMET02709 0.331 0.066 DBMET02710 0.588 0.011 DBMET02711 | DBMET02711 | |
| 0.014 | 0.607 | 0.065 | CXC chemokine 1 receptor antagonist | 0.065 0.017 DBMET02710 | DBMET02710 | |
| 0.007 | 0.604 | 0.134 | Maillard reaction inhibitor | 0.112 0.013 DBMET02709 0.134 0.008 DBMET02710 | DBMET02710 | |
| 0.023 | 0.621 | 0.086 | Interleukin 5 antagonist | 0.086 0.06 DBMET02710 | DBMET02710 | |
| 0.005 | 0.62 | 0.016 | Antibiotic Tetracycline-like | 0.016 0.008 DBMET02710 | DBMET02710 | |
| 0.008 | 0.638 | 0.212 | Tubulin antagonist | 0.157 0.055 DBMET02709 0.212 0.034 DBMET02710 | DBMET02710 | |
| 0.013 | 0.645 | 0.194 | Dual specificity phosphatase 3 inhibitor | 0.194 0.064 DBMET02710 0.173 0.079 DBMET02711 | DBMET02710 | |
| 0.052 | 0.687 | 0.236 | Papain-like protease (SARS coronavirus) inhibitor | 0.227 0.006 DBMET02709 0.236 0.005 DBMET02710 0.155 0.029 DBMET02711 | DBMET02710 | |
| 0.018 | 0.687 | 0.095 | Gonadotropin-releasing hormone receptor agonist | 0.095 0.011 DBMET02709 0.084 0.015 DBMET02710 | DBMET02709 | |
| 0.038 | 0.712 | 0.149 | Growth hormone agonist | 0.149 0.088 DBMET02710 | DBMET02710 | |
| 0.002 | 0.682 | 0.028 | Aminopeptidase P inhibitor | 0.028 0.011 DBMET02711 | DBMET02711 | |
| 0.014 | 0.698 | 0.081 | Vanilloid 2 antagonist | 0.061 0.021 DBMET02710 0.081 0.009 DBMET02711 | DBMET02711 | |
| 0.011 | 0.694 | 0.408 | Free radical scavenger | 0.408 0.027 DBMET02710 0.363 0.036 DBMET02711 | DBMET02710 | |
| 0.018 | 0.703 | 0.081 | MAP kinase 7 inhibitor | 0.081 0.043 DBMET02709 | DBMET02709 | |
| 0.019 | 0.722 | 0.166 | Interleukin 1b antagonist | 0.166 0.03 DBMET02709 0.111 0.07 DBMET02710 | DBMET02709 | |
| 0.018 | 0.73 | 0.194 | Angiogenesis inhibitor | 0.194 0.177 DBMET02709 | DBMET02709 | |
| 0.006 | 0.72 | 0.044 | Neuraminidase (Influenza A) inhibitor | 0.044 0.035 DBMET02708 0.044 0.034 DBMET02710 | DBMET02710 | |
| 0.013 | 0.73 | 0.096 | Somatostatin 1 agonist | 0.09 0.041 DBMET02710 0.096 0.037 DBMET02711 | DBMET02711 | |
| 0.03 | 0.749 | 0.171 | NOS3 expression enhancer | 0.171 0.056 DBMET02710 | DBMET02710 | |
| 0.009 | 0.747 | 0.162 | Antimitotic | 0.162 0.111 DBMET02710 | DBMET02710 | |
| 0.006 | 0.744 | 0.12 | Bronchodilator | 0.12 0.044 DBMET02710 | DBMET02710 | |
| 0.007 | 0.762 | 0.187 | Topoisomerase II alpha inhibitor | 0.187 0.017 DBMET02710 | DBMET02710 | |
| 0.005 | 0.765 | 0.105 | Butyrylcholinesterase inhibitor | 0.105 0.058 DBMET02709 | DBMET02709 | |
| 0.03 | 0.795 | 0.166 | Growth factor agonist | 0.166 0.109 DBMET02709 0.151 0.138 DBMET02710 | DBMET02709 | |
| 0.008 | 0.784 | 0.082 | Potassium channel (Ca-activated) blocker | 0.082 0.017 DBMET02709 | DBMET02709 | |
| 0.005 | 0.783 | 0.18 | Acetylcholinesterase inhibitor | 0.18 0.04 DBMET02709 0.148 0.057 DBMET02710 | DBMET02709 | |
| 0.004 | 0.782 | 0.113 | Nicotinic receptor beta4 subunit antagonist | 0.113 0.005 DBMET02711 | DBMET02711 | |
| 0.004 | 0.793 | 0.069 | Estrogen-related receptor alpha antagonist | 0.034 0.021 DBMET02709 0.069 0.009 DBMET02710 | DBMET02710 | |
| 0.007 | 0.8 | 0.079 | Phosphodiesterase 7A inhibitor | 0.079 0.007 DBMET02709 0.052 0.036 DBMET02710 | DBMET02709 | |
| 0.004 | 0.799 | 0.1 | Phosphodiesterase VII inhibitor | 0.1 0.013 DBMET02709 | DBMET02709 | |
| 0.004 | 0.803 | 0.032 | Catechol O-methyltransferase inhibitor | 0.032 0.024 DBMET02710 | DBMET02710 | |
| 0.004 | 0.806 | 0.17 | Alpha tubulin antagonist | 0.077 0.021 DBMET02709 0.17 0.008 DBMET02710 | DBMET02710 | |
| 0.021 | 0.827 | 0.145 | Interleukin 12 antagonist | 0.101 0.053 DBMET02709 0.145 0.014 DBMET02710 | DBMET02710 | |
| 0.01 | 0.827 | 0.436 | Interleukin 6 antagonist | 0.436 0.005 DBMET02709 0.383 0.008 DBMET02710 | DBMET02709 | |
| 0.003 | 0.823 | 0.03 | AMPA 2 receptor antagonist | 0.03 0.02 DBMET02709 | DBMET02709 | |
| 0.009 | 0.831 | 0.205 | Interleukin 1 antagonist | 0.205 0.031 DBMET02709 0.163 0.05 DBMET02710 | DBMET02709 | |
| 0.009 | 0.839 | 0.326 | Angiogenesis stimulant | 0.239 0.075 DBMET02709 0.326 0.04 DBMET02710 0.261 0.065 DBMET02711 | DBMET02710 | |
| 0.003 | 0.839 | 0.137 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.137 0.004 DBMET02710 | DBMET02710 | |
| 0.009 | 0.846 | 0.101 | Thioredoxin reductase inhibitor | 0.1 0.029 DBMET02709 0.101 0.028 DBMET02710 | DBMET02710 | |
| 0.023 | 0.864 | 0.519 | Sigma receptor agonist | 0.519 0.008 DBMET02709 0.446 0.015 DBMET02710 | DBMET02709 | |
| 0.004 | 0.856 | 0.058 | Dopamine agonist | 0.058 0.053 DBMET02710 | DBMET02710 | |
| 0.018 | 0.871 | 0.094 | ABCA1 expression enhancer | 0.085 0.076 DBMET02709 0.094 0.058 DBMET02710 | DBMET02710 | |
| 0.004 | 0.871 | 0.055 | Estrogen-related receptor beta antagonist | 0.055 0.005 DBMET02710 | DBMET02710 | |
| 0.012 | 0.88 | 0.061 | Adenine nucleotide translocase inhibitor | 0.061 0.026 DBMET02710 | DBMET02710 | |
| 0.005 | 0.874 | 0.155 | Protein-tyrosine phosphatase inhibitor | 0.155 0.073 DBMET02710 | DBMET02710 | |
| 0.003 | 0.875 | 0.034 | Kinesin-like protein 1 inhibitor | 0.034 0.03 DBMET02710 | DBMET02710 | |
| 0.003 | 0.875 | 0.034 | Kinesin antagonist | 0.034 0.03 DBMET02710 | DBMET02710 | |
| 0.005 | 0.884 | 0.157 | Cholinergic | 0.157 0.071 DBMET02709 | DBMET02709 | |
| 0.004 | 0.893 | 0.075 | CDC25B inhibitor | 0.075 0.033 DBMET02710 | DBMET02710 | |
| 0.005 | 0.895 | 0.64 | Interleukin antagonist | 0.144 0.122 DBMET02709 0.304 0.047 DBMET02710 0.64 0.009 DBMET02711 | DBMET02711 | |
| 0.004 | 0.895 | 0.057 | Growth hormone release inhibitor | 0.057 0.017 DBMET02711 | DBMET02711 | |
| 0.004 | 0.895 | 0.072 | HIV-1 integrase inhibitor | 0.072 0.046 DBMET02710 | DBMET02710 | |
| 0.019 | 0.916 | 0.32 | Caspase 3 stimulant | 0.32 0.069 DBMET02710 | DBMET02710 | |
| 0.011 | 0.913 | 0.151 | Toll-Like receptor 4 antagonist | 0.105 0.063 DBMET02709 0.151 0.021 DBMET02710 | DBMET02710 | |
| 0.005 | 0.907 | 0.252 | Topoisomerase II inhibitor | 0.094 0.092 DBMET02709 0.252 0.024 DBMET02710 | DBMET02710 | |
| 0.004 | 0.911 | 0.63 | Lipid peroxidase inhibitor | 0.63 0.004 DBMET02708 0.264 0.024 DBMET02710 0.195 0.044 DBMET02711 | DBMET02708 | |
| 0.005 | 0.911 | 0.145 | Nitric oxide antagonist | 0.145 0.099 DBMET02710 | DBMET02710 | |
| 0.009 | 0.918 | 0.22 | Immunosuppressant | 0.22 0.176 DBMET02710 | DBMET02710 | |
| 0.005 | 0.914 | 0.094 | Opioid kappa receptor antagonist | 0.094 0.042 DBMET02710 | DBMET02710 | |
| 0.009 | 0.925 | 0.141 | Thioredoxin inhibitor | 0.133 0.023 DBMET02709 0.141 0.02 DBMET02710 | DBMET02710 | |
| 0.01 | 0.932 | 0.122 | Nav1.1 sodium channel blocker | 0.122 0.047 DBMET02709 0.118 0.049 DBMET02710 | DBMET02709 | |
| 0.004 | 0.929 | 0.122 | Opioid antagonist | 0.122 0.035 DBMET02710 | DBMET02710 | |
| 0.005 | 0.931 | 0.048 | DNA gyrase subunit A inhibitor | 0.048 0.019 DBMET02710 | DBMET02710 | |
| 0.004 | 0.933 | 0.082 | CDC25A inhibitor | 0.082 0.041 DBMET02710 | DBMET02710 | |
| 0.003 | 0.932 | 0.121 | Opioid delta receptor antagonist | 0.121 0.026 DBMET02710 | DBMET02710 | |
| 0.003 | 0.933 | 0.051 | Dopamine D2 agonist | 0.051 0.026 DBMET02710 | DBMET02710 | |
| 0.001 | 0.931 | 0.012 | 3C-Like protease (MERS coronavirus) inhibitor | 0.012 0.008 DBMET02708 | DBMET02708 | |
| 0.003 | 0.938 | 0.082 | Opioid agonist | 0.082 0.018 DBMET02710 | DBMET02710 | |
| 0.002 | 0.943 | 0.092 | Leukotriene A4 hydrolase inhibitor | 0.092 0.007 DBMET02711 | DBMET02711 | |
| 0.003 | 0.946 | 0.088 | Opioid mu receptor antagonist | 0.088 0.036 DBMET02710 | DBMET02710 | |
| 0.002 | 0.948 | 0.085 | Opioid delta receptor agonist | 0.045 0.016 DBMET02709 0.085 0.006 DBMET02710 | DBMET02710 | |
| 0.01 | 0.96 | 0.174 | Hepatoprotectant | 0.164 0.096 DBMET02710 0.174 0.085 DBMET02711 | DBMET02711 | |
| 0.003 | 0.953 | 0.141 | Beta tubulin antagonist | 0.073 0.033 DBMET02709 0.141 0.013 DBMET02710 | DBMET02710 | |
| 0.008 | 0.96 | 0.102 | Antineoplastic alkaloid | 0.102 0.046 DBMET02710 | DBMET02710 | |
| 0.004 | 0.959 | 0.163 | Topoisomerase I inhibitor | 0.163 0.037 DBMET02710 | DBMET02710 | |
| 0.001 | 0.957 | 0.126 | Estrogen receptor alpha agonist | 0.126 0.006 DBMET02710 | DBMET02710 | |
| 0.005 | 0.963 | 0.724 | Cyclophilin D inhibitor | 0.724 0.012 DBMET02707 | DBMET02707 | |
| 0.003 | 0.963 | 0.141 | 5-Lipoxygenase inhibitor | 0.141 0.041 DBMET02710 | DBMET02710 | |
| 0.002 | 0.97 | 0.049 | Collagenase inhibitor | 0.049 0.034 DBMET02711 | DBMET02711 | |
| 0.001 | 0.974 | 0.042 | Neutral endopeptidase inhibitor | 0.042 0.009 DBMET02711 | DBMET02711 | |
| 0.001 | 0.975 | 0.14 | Estrogen receptor beta agonist | 0.14 0.008 DBMET02710 | DBMET02710 | |
| 0.002 | 0.977 | 0.03 | Geranylgeranyltransferase I inhibitor | 0.03 0.008 DBMET02711 | DBMET02711 | |
| 0.005 | 0.979 | 0.215 | Hypoglycemic | 0.215 0.099 DBMET02710 | DBMET02710 | |
| 0.005 | 0.98 | 0.186 | Farnesoid X receptor antagonist | 0.186 0.026 DBMET02710 | DBMET02710 | |
| 0.005 | 0.986 | 0.084 | Vanilloid agonist | 0.084 0.06 DBMET02710 | DBMET02710 | |
| 0.002 | 0.987 | 0.043 | Opioid mu receptor agonist | 0.043 0.037 DBMET02710 | DBMET02710 | |
| 0.003 | 0.988 | 0.285 | Estrogen receptor beta antagonist | 0.285 0.005 DBMET02710 | DBMET02710 | |
| 0.003 | 0.989 | 0.1 | Farnesyltransferase inhibitor | 0.1 0.007 DBMET02711 | DBMET02711 | |
| 0.003 | 0.992 | 0.078 | Analgesic, opioid | 0.078 0.05 DBMET02710 | DBMET02710 | |
| 0.003 | 0.995 | 0.269 | Estrogen antagonist | 0.269 0.008 DBMET02710 | DBMET02710 | |
| 0.002 | 0.994 | 0.085 | Angiotensin-converting enzyme inhibitor | 0.085 0.012 DBMET02711 | DBMET02711 | |
| 0.002 | 0.995 | 0.161 | Estrogen agonist | 0.161 0.01 DBMET02710 | DBMET02710 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |